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ABSTRACT 
Mesenchymal stromal cells (MSCs) are adult, multipotent cells of mesodermal 
origin representing the progenitors of all stromal tissues. MSCs possess 
significant and broad immunomodulatory functions affecting both adaptive and 
innate immune responses once MSCs are primed by the inflammatory 
microenvironment. Recently, the role of extracellular vesicles (EVs) in mediating 
the therapeutic effects of MSCs has been recognized. Nevertheless, the molecular 
mechanisms responsible for the immunomodulatory properties of MSC-derived 
EVs (MSC-EVs) are still poorly characterized. Therefore, we carried out a 
molecular characterization of MSC-EV content by high-throughput approaches. 
We analyzed miRNA and protein expression profile in cellular and vesicular 
compartments both in normal and inflammatory conditions. We found several 
proteins and miRNAs involved in immunological processes, such as MOES, 
LG3BP, PTX3, and S10A6 proteins, miR-155-5p, and miR-497-5p. Different in 
silico approaches were also performed to correlate miRNA and protein expression 
profile and then to evaluate the putative molecules or pathways involved in 
immune regulatory properties mediated by MSC-EVs. PI3K-AKT signaling 
pathway and the regulation of actin cytoskeleton were identified and functionally 
validated in vitro as key mediators of MSC/B cell communication mediated by 
MSC-EVs. In conclusion, we identified different molecules and pathways 
responsible for immune regulatory properties mediated by MSC-EVs, thus 
identifying novel therapeutic targets as safer and more useful alternatives to cell 
or EV-based therapeutic approaches.  
 
 
 
 
 
 
 
 
 
SOMMARIO 
Le cellule mesenchimali stromali (MSCs) sono cellule adulte multipotenti di 
origine mesodermica e rappresentano i progenitori di tutti i tessuti stromali. Le 
MSCs posseggono significative proprietà immunomodulatorie nei confronti delle 
cellule dell’immunità innata e adattiva, specialmente quando si trovano in un 
ambiente infiammatorio. L’effetto terapeutico delle MSCs è in parte mediato dal 
rilascio di vescicole extracellulari (EVs) ma i meccanismi molecolari alla base 
delle capacità immunomodulatorie delle EVs secrete dalle MSCs (MSC-EVs) non 
sono stati ancora caratterizzati. In questo studio abbiamo effettuato una 
caratterizzazione molecolare del contenuto delle MSC-EVs tramite approcci high-
throughput. In particolare, abbiamo analizzato il profilo di espressione di miRNAs 
e proteine nel compartimento vescicolare e cellulare in condizioni normali e 
infiammatorie. I risultati ottenuti mostrano numerose molecole differenzialmente 
espresse nella condizione infiammatoria rispetto al controllo, le quali includono le 
proteine MOES, LG3BP, PTX3 e S10A6, e i miRNAs miR-155-5p, and miR-497-
5p.  Inoltre, abbiamo messo a punto diversi approcci in silico per correlare i profili 
di espressione di miRNAs e proteine al fine di valutare le singole molecole e i 
pathway coinvolti nell’effetto immunoregolatorio mediato dalle MSC-EVs. Il 
pathway “PI3K-AKT” e la “regolazione del citoscheletro di actina” sono stati 
identificati e validati funzionalmente in vitro quali mediatori chiave della 
comunicazione tra MSCs e cellule B mediata dal rilascio di EVs. In conclusione, 
abbiamo identificato alcune molecole e specifici pathway responsabili delle 
proprietà immunoregolatorie che caratterizzano le MSC-EVs, i quali potranno 
rappresentare nel futuro nuovi target terapeutici e un’alternativa più sicura rispetto 
agli approcci terapeutici basati sull’utilizzo diretto di MSCs o MSC-EVs. 
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1. INTRODUCTION 
 
1.1 Extracellular Vesicles 
Intercellular communication amongst neighboring cells usually occurs either 
through cell-to-cell contact or exchange of soluble factors. The latter mechanism 
rarely occurs through the simple secretion of molecules in the intercellular space, 
which would lead to their rapid inactivation especially if released at tiny 
concentrations. A very effective, physiological intercellular communication, even 
at low molecule concentrations, is represented by the exchange of extracellular 
vesicles (EVs). EVs consist of a membrane-like envelope, i.e. spherical 
phospholipid bilayer surrounding various molecules, such as proteins, DNA, 
different types of RNAs (mRNAs, miRNAs and lncRNAs), lipids and active 
metabolites. EVs are shedding vesicles acting as molecular shuttles, constantly 
released by the cells in a sort of assembly chain process, which are characterized 
by different size and molecular content according to their origin, biogenesis and 
cellular functional status (1-4). EVs include exosomes (50-100 nm), microvesicles 
(100-1000 nm), apoptotic bodies (1-5 µm) and some other membrane-bound 
particles. Exosomes originate from multivesicular body and contain common 
protein families, such as chaperones (Hsp70 and Hsp90), cytoskeletal proteins 
(actin, myosin and tubulin), ESCRT proteins (TSG-101 and Alix), proteins 
involved in transport and fusion (Rab11, Rab7, Rab2 and Annexines) as well as 
tetraspanin proteins (CD9, CD63, CD81 and CD82) (5-7). Microvesicles result 
from plasmatic membrane gemmation and contain specific cytoplasmatic proteins 
of the cells of origin, such as GTP-binding protein, ADP-ribosylation factor 6 
(ARF6), matrix metalloproteinases (MMPs), glycoproteins (e.g. GPIb, GPIIb-
IIIa), integrins, receptors (e.g. EGFRvIII) and cytoskeletal components (e.g. β-
actin and α-actinin-4) (5, 6). In addition, both exosomes and microvesicles contain 
a large number of molecules, whose functions are still under investigation (8). By 
contrast, apoptotic bodies are functionally different by the other two kinds of EVs, 
as they result from the programmed cell death mechanisms and contain DNA, 
histones and cellular debris derived from cell dismantlement; their formation is a 
highly controlled mechanism preventing leakage of potentially toxic, 
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enzymatically active or immunogenic components of dying cells, thereby 
preventing tissue destruction, inflammation, and autoimmune reactions through 
cytoskeleton weakening and activation of caspase enzymes. In addition, apoptotic 
bodies act as a powerful signaling pathway for the microenvironment surrounding 
dying cells (1-4). 
The secretion of EVs is not restricted to mammalian cells, but it has been also 
identified in lower eukaryotes and prokaryotes, highlighting a high degree of 
conservation of such communication system and, consequently, its relevance in 
intercellular communication (9, 10). EVs influence various biological processes 
directly activating cell surface receptors through protein and bioactive lipid 
ligands, and delivering effectors including transcription factors, oncogenes, 
mRNAs, and non-coding regulatory RNAs, such as miRNAs into target cells (11-
13). 
EVs play a role also during the onset of immune responses. EVs isolated from 
different cell types possess immunosuppressive effects on T cells and NK cells 
and play a crucial role in the induction of regulatory T and myeloid cells to further 
inhibit the immune response (14-16). EVs in co-culture with peripheral blood 
mononuclear cells (PBMCs) inhibit B cell proliferation and immunoglobulin 
release (17). Placenta-derived exosomes, purified from the blood of pregnant 
women, carry immunosuppressive molecules, such as Fas-ligand, which induce 
tolerance towards the fetus (1-4). On the other hand, EVs may also stimulate the 
immune system, with the final effect depending on many factors, such as effector 
and target cells as well as the biological context in which this interaction takes 
place (1, 4, 18). 
 
1.2 Mesenchymal Stromal Cells and Immunomodulation 
Mesenchymal stromal cells (MSCs) are adult, multipotent cells of mesodermal 
origin representing the progenitors of all stromal tissues. In fact, although they 
were first identified and isolated from bone marrow (BM), MSCs can be 
expanded from virtually any tissue with a stromal architecture, including adipose 
tissue, umbilical cord blood, skin, tendon, muscle, and dental pulp (19-22). 
The Mesenchymal and Tissue Stem Cell Committee of the International Society 
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for Cellular Therapy proposed minimal criteria to define human MSCs. First, 
MSCs must be plastic-adherent when maintained in standard culture conditions. 
Second, MSC must express CD105, CD73 and CD90, and lack expression of 
CD45, CD34, CD14 or CD11b, CD79alpha or CD19 and HLA-DR surface 
molecules. Third, MSCs must differentiate into osteoblasts, adipocytes and 
chondroblasts in vitro (23). Considering their stem properties, the therapeutic 
potential of MSCs has been increasingly studied in the field of regenerative 
medicine (24, 25). However, MSCs possess also significant and broad immune 
modulatory functions affecting both adaptive and innate immune responses once 
MSCs are primed by the inflammatory microenvironment (26). MSC-mediated 
immune regulation has been confirmed by both preclinical and clinical studies 
based on systemic or local MSC administration in a broad spectrum of 
inflammatory and autoimmune diseases, such as Graft-versus-Host Disease 
(GvHD) (27), Crohn’s disease and enteropathies (28-30), as well as in 
cardiovascular disease (31, 32), acute kidney injury (33), colitis, sepsis (34), and 
other disorders (35). MSCs can inhibit natural killer cell (NK) proliferation and 
activity, T lymphocyte proliferation, dendritic cells (DCs) maturation and B 
lymphocyte proliferation and activation. Moreover, MSCs may induce regulatory 
T cell (Treg) expansion (36). The beneficial effect of MSCs was initially ascribed 
to their ability to home within the inflammation sites, thus stimulating endogenous 
repair of the injured tissue and modulating immune responses (37-39); actually, 
only a negligible percentage of systemically administered MSCs is capable of 
reaching the damaged tissues (40, 41). Therefore, MSC biological activity - in 
terms of both regeneration and immunomodulation – is supposed to reside in their 
ability to act at paracrine level through the release of bioactive factors, as 
observed with cardiomyocytes exposed to hypoxia/reoxygenation (42), or through 
indirect mechanisms involving phagocytes (43). Several studies identified soluble 
mediators involved the MSC-immune-modulatory effects, such as interleukins 
(IL) 6 and 10, prostaglandin E2 (PGE2), hepatocyte growth factor (HGF), 
indoleamine 2,3-dioxygenase (IDO), nitric oxide (NO), transforming growth 
factor (TGF)-1 and human leukocyte antigen G (HLA-G) (36).  
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1.3 Mesenchymal stromal cell-derived extracellular vesicles and 
Immunomodulation 
Recently, the role of EVs in mediating the paracrine effects of MSCs in tissue 
repair and immunomodulation has been recognized both in vitro and in vivo (44, 
45). Several studies reported an inhibitory activity of MSC-EVs on B, T and NK 
cell proliferation and activation (45, 46). Moreover, MSC-EVs may polarize 
monocytes toward M2-like phenotype, which in turn induces CD4+ T cell to 
differentiate into regulatory T cells (47). Blazquez et al. also reported the 
capability of MSC-EVs to inhibit the release of inflammatory cytokines by 
activated T cells, including IFN-γ (48). In addition, Favaro et al. showed that 
MSC-EVs were able to inhibit IFN-γ production in PBMCs isolated from type 1 
diabetic patients, increasing the release of immunomodulatory molecules such as 
PGE-2, TGF-β, IL-10, and IL-6 and the percentage of regulatory T-cells (49, 50). 
Furthermore, dendritic cells conditioned with MSC-EVs acquire an immature 
phenotype with increased IL-10 secretion, thus inducing a reduction of 
inflammatory T-cell response (49-51). 
The therapeutic potential of MSC-EVs in terms of immune regulation has been 
observed in vivo in different disease models. MSC-EV administration reduced 
Acute Kidney Injury (AKI)-induced oxidative stress, apoptosis and fibrosis (52, 
53), and the reduction of pro-inflammatory and an increase of anti-inflammatory 
cytokines (54, 55). Furthermore, AKI-induced invasion of macrophages and 
lymphocytes was suppressed following the treatment with MSC-EVs (53, 56, 57). 
Similar results were observed in acute myocardial infarction (58, 59), liver disease 
(35, 60, 61), brain and lung injury (62-64). 
In a mouse model of acute GvHD, MSC-EVs recapitulated the therapeutic effects 
of MSCs (65). Systemic infusion of MSC-EVs prolonged the survival and reduced 
the pathologic damage in multiple GvHD-targeted organs, in association with a 
suppression of both CD4+ and CD8+ T cells (65). 
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1.4 Clinical translation of MSC-EVs: unresolved issues and future 
perspectives 
The use of stem cells for the therapy of human disease, including inflammatory 
disorders, raised several concerns in the past years leading to challenging 
objectives to overcome. Such challenges are represented by immune-mediated 
rejection, senescence-induced genetic instability or loss of function, limited cell 
survival and malignant transformation (31). In order to produce a sufficient 
amount of MSCs for clinical application, a considerable in vitro expansion is 
required, leading to potential spontaneous cell transformation (66). Genetic 
manipulation of MSCs can increase the oncogenic potential of the cells; the 
transgene may be tumorigenic or cause disruptions in the genome. Furthermore, 
MSCs are strongly involved in tumor development and various studies reported 
MSCs as potential source of tumor associated fibroblasts (67). In this light, the 
choice of translating the therapeutic potential of MSCs to the clinic should be 
cautiously considered. Experimental studies showed that only a small proportion 
of MSCs, locally or systematically administered, were incorporated into injured 
tissues, indicating that the beneficial effects in tissue repair and 
immunosuppression is mainly mediated by the paracrine activity of MSCs, that 
includes the release of EVs. This intriguing hypothesis opens novel therapeutic 
perspectives aimed at developing cell-free strategies based on the use of MSC-
EVs.  
 
1.4.1 Tumorigenesis and other potential adverse effects of MSC-EVs 
Although EVs clearly lack the potential to directly develop tumors following in 
vivo administration, this does not imply that MSC-EVs administration to human is 
without any risk of promoting neoplasia. Roccaro et al. isolated EVs from BM-
MSCs derived from both multiple myeloma patient and healthy controls. In this 
study, patient-derived MSC-EVs promoted tumor cell growth, whereas healthy 
donor-derived MSC-EVs inhibited tumor growth both in vitro and in vivo (68). 
MSC-EVs are able to modulate the tumor microenvironment, thus creating a niche 
for cancer cell metastasis and have been found to mimic the effect of MSCs in 
promoting tumor growth. Zhu et al. showed that MSC-EVs co-implanted with 
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human gastric cancer cells increased tumor growth and angiogenesis (69). 
However, contradictory results have been reported. Some authors have 
demonstrated an inhibitory effect towards tumor growth in terms of angiogenesis, 
drug resistance and cell proliferation (70, 71). The controversial data on the effect 
of MSC-EVs on tumor growth highlight the complexity of their functions, that 
could be even opposite depending on several factors, such as the type and the 
tissue origin of MSCs; in addition, cancer cells may show different responses 
depending on the tumor model considered. Therefore, it is crucial to carefully 
evaluate the short- and long- term safety of biologically active EVs for a 
successful translation of MSC-EVs as a clinical therapy. 
 
1.4.2 Large scale MSC-EVs production for clinical use 
Although MSCs are relatively easy to expand using conventional methods, their 
growth in culture is finite and their biological properties may become altered with 
repeated passage. To facilitate large-scale MSC-EV production, new batches of 
MSCs will have to be periodically derived with significant impact on costs of 
derivation, testing, and validation. MSC immortalization by natural selection or 
by genetic modification or clonal isolation could be used to overcome this 
limitation although it would entail safety issues. Chen et al. proposed a robust 
scalable manufacturing process for therapeutic EVs through oncogenic 
immortalization of human embryonic stem cells (ECS)-derived MSCs (72). In 
order to enhance purity and yield of MSC-EVs preparation, several approaches 
have been evaluated, including sequential centrifugation, filtration, and sucrose 
density gradient to remove contaminating protein aggregates, cell debris and 
genetic material (73-75). Furthermore, standardized protocols for isolation, 
quantification and characterization of EVs are still required to clarify their 
potential clinical applications. Furthermore, because of the capacity of EVs to 
encapsulate molecules, including proteins and nucleic acids, therapeutic strategies 
based on engineered EVs are currently on study and the preliminary results are 
quite promising, thus supporting encouraging prospects for clinical applications. 
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2. AIMS OF THE STUDY 
 
The beneficial effects possessed by MSCs are reproduced by EVs they release in 
terms of both regenerative medicine and immunomodulation. The inflammatory 
environment influences their biological function inducing a higher 
immunosuppressive activity. Nevertheless, the molecular mechanisms responsible 
for the immunomodulatory role of MSC-derived EVs are still poorly 
characterized. This project started from a high-throughput characterization of 
miRNA and protein expression in MSCs at resting conditions (control MSCs, 
cMSCs), inflammatory conditions (primed-MSCs, pMSCs) and corresponding 
EVs (cEVs and pEVs, respectively). Modulated molecules were then functionally 
validated. In particular, we focused our analysis on those involved in the crosstalk 
between MSCs and B cells for the following reasons: i. our and other groups have 
previously demonstrated that B cell activity is strongly modulated by EVs 
released by MSCs (45, 76); ii. the characterization of the EV-mediated 
interactions between normal B cells and MSCs represents the basis for studying 
the same crosstalk in inflammatory and autoimmune diseases as well as in 
hematological malignancies (77-79). Therefore, the present project was aimed at 
studying the undisclosed molecular mechanisms regulating the 
immunosuppressive capability mediated by MSC-EVs. Once these mechanisms 
are identified, they may represent some novel potential therapeutic targets as safer 
and more useful alternatives to cell or EV-based therapeutic approaches for 
inflammatory, autoimmune and proliferative disorders. 
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3. MATERIALS AND METHODS 
 
Cell cultures 
MSCs were isolated from BM aspirates of healthy donors (informed consent, 
approved by Ethical Committee of Azienda Ospedaliera Universitaria Integrata 
Verona; N. 1828, May 12, 2010 “Institution of cell and tissue collection for 
biomedical research in Onco-Hematology”) and characterized as already 
described (80, 81). Briefly, bone marrow samples from healthy donors were 
seeded in 5-layer flask at 50.000/cm2 nucleated cells density using DMEM 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin-
streptomycin and 2% L-Glutamine (all from Sigma-Aldrich). After 72 hours, non-
adherent cells were removed, and the medium was replaced twice a week. MSCs 
were detached (0.05% Tripsin-EDTA; Gibco) and harvested when 80% confluent, 
and then either reseeded at 4.000/cm2 cellular density or frozen until use. At the 
end of P0 (day 12 ± 2), phenotypic analysis of cell surface markers was evaluated 
by flow cytometry. All experiments were performed between passages 2 and 7. 
MSCs at 80% confluence were treated or not for 48 hours with 10 ng/mL IFN-γ 
and 15 ng/mL TNF-α (R&D Systems) to induce inflammatory priming. PBMCs 
were isolated from human blood using Lymphoprep (Stemcells Technologies). B 
lymphocytes were isolated from PBMCs using immunomagnetic negative 
selection (Miltenyi Biotec) with at least 95% cell purity, as evaluated by flow 
cytometry (80, 81). B lymphocytes were cultured in RPMI medium supplemented 
with 10% FBS, 1% penicillin-streptomycin and 2% L-Glutamine (all from Sigma-
Aldrich). B lymphocytes were activated with 5 μg/mL anti-human IgM+IgA+IgG 
(F(ab’)2, Jackson Immunoresearch), 50 IU/mL rhIL-2 (Novartis), 50 ng/mL 
polyhistidine-tagged CD40 ligand, 5 μg/mL anti-polyhistidine antibody (R&D 
Systems), and 0.5 μg/mL CpG ODNs (Invitrogen). 
 
Purification, characterization and quantification of MSC-derived EVs 
EVs were isolated from conditioned medium by ultracentrifugation as already 
described (45). Briefly, culture medium (CM) from MSC culture at 80% 
confluence was aspirated. Cells were washed with phosphate-buffered saline 
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(PBS) to remove the residual FBS, and fresh culture medium supplemented with 
10% EV-depleted FBS, obtained through 18 hour-centrifugation at 100.000 x g 
was added. After 2 days of incubation, CM from MSCs previously treated or not 
with inflammatory cytokines was collected and underwent different steps of 
centrifugation. CM was centrifuged for 10 minutes at 300 x g, 30 minutes at 4 °C 
at 2000 x g to remove cell debris and apoptotic bodies, and then 90 minutes at 4 
°C at 100.000 x g to collect EVs. The pellet was washed with PBS thorugh 
another step of ultracentrifugation at 100.000 x g for 90 minutes at 4 °C to 
concentrate and purify EVs. EVs were then resuspended in PBS and stored at − 80 
°C. EVs quantification was performed through BCA Protein Assay (Thermo 
Fisher Scientific). Particle size was evaluated by dynamic light scattering (DLS) 
measurements using a Zetasizer Nano ZS (Malvern Instruments, 4 mV He-Ne 
laser, λ0=633 nm, θ=173°). To assess the surface marker profile, 10 µg of EVs 
were analyzed using MACSPlex Exosome Kit (Miltenyi Biotec), a multiplex 
bead-based platform that allows the detection of 37 surface epitopes. Samples 
were analyzed with a FACS Canto II (BD Bioscences). Mean fluorescence values 
were background corrected according to the protocol. 
 
EV internalization and fluorescence microscopy 
To assess EV internalization by B lymphocytes, MSC membranes and RNA were 
stained with 200 µM Vybrant Dil Cell-labeling Solution and 500 nM Syto RNA 
Select (both from Life Technologies), respectively. Then, labelled or unlabeled 
MSCs were co-cultured in presence of B lymphocytes (1:1) and EV 
internalization was assessed after 24, 48 and 72 hours. At the end of co-culture, 
cells were stained with anti-CD45-PerCP-Vio770 (Miltenyi Biotec) and TOPRO-
3. EV uptake was analyzed by flow cytometry. Furthermore, EVs were directly 
stained with 10 µM Vybrant Dil Cell-labeling Solution and 10 µM Syto RNA 
Select and washed with Exosome Spin Column (MW 3000) (Thermo Fisher 
Scientific). Then, activated B lymphocytes were cultured for 48 hours with 100 µg 
of labelled or unlabeled EVs. Cells were loaded into the CytoSpin centrifuge’s 
sample chamber and centrifuged 300xg for 5 minutes. Finally, cells were stained 
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with 1 µg/mL Hoechst (Thermo Fisher) in PBS and then analyzed by fluorescence 
microscopy using a Zeiss Axio Observer Z1 microscope (Carl Zeiss). 
 
Sample preparation for shotgun proteomics 
EVs were collected and lysed in PBS supplemented with protease inhibitors 
(Roche) and 1% Sodium Dodecyl Sulphate (SDS) (Bio-Rad). Protein extraction 
was performed by 5-6 cycles of sonication. Then, ice-cold acetone was added to 
samples and protein precipitation was conducted overnight at -20°C. Samples 
were then centrifuged at 14,000xg for 10 min at 4°C, and pellet was resuspended 
in 100 mM NH4HCO3. Protein concentration was measured with BCA Protein 
Assay. Samples were subjected to denaturation with trifluoroethanol, reduced 
with DTT 200 mM, alkylation with Iodoacetamide 200 mM, and digested with 
Trypsin/Lys-C (Promega). The peptide digests were desalted on the Discovery® 
DSC-18 solid phase extraction (SPE) 96-well Plate. The SPE plate was 
preconditioned with 1 ml of acetonitrile and 2 ml of water. After the sample 
loading, the SPE was washed with 1 ml of water. The adsorbed proteins were 
eluted with 800 μl of acetonitrile:water (80:20). After the desalting, the sample 
was vacuum-evaporated and reconstituted with 20 μl of 0.05% formic acid in 
water before LC-MS/MS analysis. 
 
Shotgun Mass Spectrometry 
The digested proteins were analyzed with a micro-LC Eksigent Technologies 
(Eksigent) system interfaced with a 5600+ TripleTOF system (AB Sciex) 
equipped with DuoSpray Ion Source and Calibrant Delivery System. More 
detailed information on instrument setting and label-free quantification is 
available in Supplementary Materials and Methods. Two DDA and three DIA 
acquisitions were performed (82). 
The DDA files were searched using Protein Pilot software v. 4.2 and Mascot v. 
2.4. Trypsin/Lys-C as digestion enzyme was specified for both the software. For 
Mascot we used 2 missed cleavages, the instrument was set to ESI-QUAD-TOF 
and the following modifications were specified for the search: carbamidomethyl 
cysteines as fixed modification and oxidized methionine as variable modification. 
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A search tolerance of 50 ppm was specified for the peptide mass tolerance, and 
0.1 Da for the MS/MS tolerance. The charges of the peptides to search for were 
set to 2 +, 3 + and 4 +, and the search was set on monoisotopic mass (83, 84). 
The UniProt Swiss-Prot reviewed database containing human proteins (version 
2015.07.07, containing 42131 sequence entries) was used and a target-decoy 
database search was performed. False Discovery Rate was fixed at 1%. 
The protein quantification was performed by integrating the extracted ion 
chromatogram of all the unique ions for a given peptide and was carried out with 
PeakView 2.0 and MarkerView 1.2. Six peptides per protein and six transitions 
per peptide were extracted from the SWATH files. Shared peptides were excluded 
as well as peptides with modifications. Peptides with FDR lower than 1.0% were 
exported in MarkerView for the t-test (85). 
Proteomic t-test statistical analysis was performed with MarkerView. Proteins 
were considered modulated in presence of a fold change ≥ 1.50 or ≤ 0.5 and a p-
value < 0.05. 
 
Western Blot Analysis  
Immunoblot analysis on EV candidate proteins was performed as previously 
described (86). Briefly, protein samples from different biological replicates were 
diluted 1:1 with Laemmli’s sample buffer (62.5 mM Tris-HCl, pH 6.8, 25% 
glycerol, 2% SDS, 0.01% Bromophenol Blue), heated for 5 min at 90°C, and 
separated by SDS/polyacrylamide gel electrophoresis (PAGE) on 4-20% T 
acrylamide gels in Tris/glycine/SDS buffer. After separation on SDS-PAGE, 
proteins were electroblotted on PVDF membrane and subjected to 
immunodetection. Amido Black staining (Sigma-Aldrich) was used to confirm 
equal protein loading in different lanes. Membranes were incubated with the 
different primary antibodies diluted in 1% non-fat dried milk, 0.05% Tween-20 in 
Tris-buffered saline for 3 hours at room temperature. Blots were then incubated 1 
hour at room temperature with the appropriate horseradish peroxidase (HRP)-
conjugated secondary antibody (see the Supplementary information, Table S8). 
Immunocomplexes were visualized by chemiluminescence using the Chemidoc 
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MP imaging system (Bio-Rad) and the intensity of the chemiluminescence signal 
was measured by processing the image with Image Lab software (Bio-Rad). 
 
Univariate and multivariate statistical analysis 
Proteomic data were analyzed by univariate and multivariate statistical analyses. 
The univariate approach consisted in selecting proteins modulated at least in 4 
samples among 7 processed samples using a cut off with adjusted p values of 
<0.05 and fold change of >1.5 or <0.0667. Principal Component Analysis (PCA) 
was applied to provide a general overview of the correlations existing between the 
variables and the existence of sample groups (see Supplementary Materials and 
Methods). PCA is exploited in Ranking-PCA to select the most discriminating 
variables (i.e. candidate biomarkers) between two groups of samples and sort 
them according to their decreasing discrimination ability (87-90). 
PLS is a multivariate regression method establishing a relationship between one 
or more dependent variables (Y) and a group of descriptors (X). X and Y 
variables are modeled simultaneously, to find the latent variables (LVs) in X that 
will predict the LVs in Y. PLS can be applied for classification purposes by 
establishing an appropriate Y related to the association of each sample to a class. 
Since two classes are present in this case (control and primed samples), a binary Y 
variable is added to each dataset, coded so that − 1 is attributed to control samples 
and +1 to primed samples. The regression is then carried out between X-block 
variables (protein counts) and the Y just established. This application for 
classification purposes is called PLS-DA (91). Here, Ranking-PCA was used as 
selection method to provide the list of all candidate biomarkers in decreasing 
order of discriminant ability of the final model. The list identified in this way was 
then used for classification, based on PLS-DA (Marengo et al. 2008), to provide a 
final model able to discriminate the two classes of samples present. The analysis 
was done considering 1 PC in Ranking-PCA and 1 LV in the final PLS-DA 
models (for MSCs, only the first 200 proteins selected by Ranking-PCA were 
included in the PLS-DA model). Both the selection of the significant proteins by 
Ranking-PCA and the calculation of the performance ability of the PLS-DA 
models were obtained by leave-one-out (LOO) cross-validation: all the 
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replications of the same sample (both control and primed replications) were 
eliminated in turn from the calculation and used to provide an evaluation of the 
final predictive ability. Since 7 individuals were available, only LOO was applied, 
and one individual was eliminated at a time. In Ranking-PCA just one PC was 
used for calculation, due to the small number of degrees of freedom available. The 
classification performances were evaluated by calculating model accuracy, i.e. the 
ratio of correctly assigned samples, and the Non-Error-Rate% (NER%), i.e. the 
average of the accuracies calculated for each class independently. 
 
RNA extraction and quality controls 
Total RNA was extracted using miRNeasy Mini Kit (Qiagen) and miRNA 
enriched fraction was obtained using mirPremier microRNA Isolation Kit (Sigma 
Aldrich) according to manufacturer’s instructions. RNA was quantified with the 
Qubit RNA Assay kit (Life Technologies). RNA purity and integrity were 
assessed at the Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific) and 
by capillary electrophoresis on an Agilent Bioanalyzer (Agilent Technologies), 
respectively. 
 
Small RNA Sequencing 
Small RNA libraries were prepared using the NebNext Small RNA Library 
Preparation Kit (New England Biolabs) for miRNA and short non-coding RNAs 
sequencing according to manufacturer’s instructions, starting from 200 ng RNA 
and using 15 PCR cycles. Each library was analyzed with the High Sensitivity 
DNA chip (Agilent) using Agilent 2100 Bioanalyzer. Pools of 12 libraries were 
concentrated with AMPure XP magnetic beads (Beckman Coulter) and eluted in 
40 µl of nuclease free water. The eluate from each pool was loaded onto a 6% 
precast gel (Life Technologies), a ≈146 bp band was cutted, purified with a 5 μL 
filter with Qiaquick gel extraction kit (Qiagen) and quantified using the Qubit 
DNA HS (Life Technologies). The miRNAseq libraries were sequenced on a 
NextSeq500 sequencer (Illumina) using 75bp-reads and producing on average 
20470347,38 reads per sample. 
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Identification of differentially expressed miRNAs 
Illumina sequencing was used to generate small RNA reads from 9 biological 
replicates of primed and control EVs/MSCs. Raw fastq files were analyzed to 
evaluate their quality using FastQC software 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc). Adapter trimming 
was performed using TrimGalore specifying length and max-length parameters 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore). After this 
step, only reads with length between 16 and 26 nucleotides remained for further 
analysis. Clipped reads were aligned using Bowtie2 to the GRCh38 human 
genome built from ENSEMBL, using the preset of parameters very-sensitive-local 
to obtain high-score matches (92). The summarization of the reads was performed 
using featureCounts (93), using the GFF annotation file provided by miRBase. 
Differential expression analysis was conducted through the R/Bioconductor 
package DESeq2 comparing primed versus control EV/MSC samples, using a 5% 
FDR cut-off (94). 
 
Real-time qPCR 
For miRNA analysis, 10 ng of RNA was retro-transcribed with TaqMan 
MicroRNA Reverse Transcription Kit (Applied Biosystems). Relative miRNA 
expression was determined using TaqMan Universal Master Mix II, no UNG and 
Taqman microRNA assay (Applied Biosystems) and normalized to U6. All 
reactions were performed in triplicates and run on LightCycler 480 Instrument II 
(Roche) following manufacturer’s instructions. Data obtained from the qPCR 
were analyzed using the ΔΔCt method. 
 
GO annotation and pathway enrichment analysis of differentially expressed 
proteins 
GO annotation of significantly altered proteins expressed in pEVs was performed 
with DAVID v6.8 Functional Annotation Bioinformatics Tools 
(https//david.ncifcrf.gov/). The enrichment analysis for GO cellular component, 
biological process and molecular function was done by comparing the GO terms 
of identified proteins against the human proteome. This analysis detected the 
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significant (p adj < 0.05) over-representation of GO terms in the submitted 
dataset. In addition, ClueGO v2.3.3, was used for analyzing significantly enriched 
KEGG pathways (p adj < 0.05) with the human genome as background (95). The 
nodes in functionally grouped networks were linked based on their kappa score 
level (0.4) in ClueGO; the GO Tree Levels ranged from levels 3–8. 
 
GO annotation and pathway enrichment analysis of modulated miRNAs and 
miRNA targets 
Functional enrichment of top 10 (based on adjusted p-value) differentially 
expressed miRNAs in pEVs and pMSCs was performed using DIANA-miRPath 
v3.0 (96). The enrichment analysis was conducted on KEGG and GO using only 
experimentally validated miRNA-target interactions provided by DIANA-TarBase 
v7.0, with genes union as merging algorithm. Furthermore, the parameter 
conservative stats were used to have a more stringent statistical test. Only terms 
with an adjusted p-value < 0.01 were selected. 
 
In vitro cell spreading 
Glass coverslips were coated at room temperature for 2 hours with 5 μg/mL of 
F(ab’)2. 15x104 B lymphocytes, pre-treated for 24 hours with resting and primed 
EVs, were left to spread at 37°C on coverslips for different time points. Then, 
cells were fixed with 4% paraformaldehyde in PBS (ChemCruz), permeabilized 
with 0.5% Triton X-100 (AppliChem) and stained with DAPI and rhodamine 
phalloidin (both from Life Technologies). Cell spreading was quantified by 
measuring the mean cell area (µm2) by using AxioVision 4.8.2 software (Carl 
Zeiss). 
 
miRNA mimic transient transfection 
Activated B cells were seeded at 2x105/200 µL per well. After 24 hours, cells 
were transfected with 10 nM of miR-155-5p mimic 
(5'UUAAUGCUAAUCGUGAU AGGGGU) or negative control miRNA 
(5’GAUGGCAUU CGAUCAGUUCUA) both from Exiqon using INTERFERin 
(Polyplus-transfection S.A.). After 6 hours, complete RPMI medium 
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supplemented with stimuli was added to each well. Finally, cells were harvested 
for the functional analyses after 24, 96 or 120 hours. 
 
PI3K/AKT signaling pathway expression profile 
B lymphocytes were cultured for 4 days in presence or absence of EVs (30 μg 
EVs/2x104 cells) or transfected with miRNA Mimics. At the end of culture, cells 
were harvested and stained with CD45-PerCpVio700 and Viobility 405/520 
Fixable Dye (both from Miltenyi Biotec). Then, cells were fixed and 
permeabilized using Cell Signalling Buffer Set A (Miltenyi Biotec) and stained 
with Anti-AKT pS473-Vio515, Anti-AKT Pan (PKB)-APC, Anti-GSK3B pS9-
PE, Anti-p70 S6 Kinase-FITC, Anti-S6 pS235/pS236-PE and Anti-S6 pS240-
APC (all from Miltenyi Biotec) according to manufacturer’s instructions. Protein 
expression was assessed by flow cytometry. Data analysis was performed using 
FlowJo software (TreeStar). Data were expressed as mean ± SEM. Statistical 
analysis was performed by Pism software (GraphPad) using the Wilcoxon test. P< 
0.05 was considered statistically significant. 
 
Cell Proliferation and Viability Assay 
To evaluate the effect of selected miRNAs on B cell proliferation, cells were 
activated and stained with 5 μM carboxyfluorescein succinimidyl ester (CFSE, 
Life Technologies). After 24 hours, cells were transfected with miRNA mimics 
and negative control. After 4 days, cells were harvested and stained with anti-
human CD45-PerCP-Vio700 (Milteniy Biotec) and TOPRO-3 Iodide (Life 
Technologies). The effect of selected miRNA on cell viability was assessed by 
flow cytometry using AnnexinV/7AAD staining. Following 24 hour-stimulation, 
cells were transfected with miRNA mimics and negative control. After 24 hours, 
cells were harvested and stained with anti-human CD45-APC (Milteniy Biotec), 
Annexin V-FITC (Milteniy Biotec) and 7AAD (BD Biosciences). Cell viability 
was evaluated on CD45posAnnexin Vneg 7AADneg cells using FlowJo software 
(TreeStar). Data were expressed as mean ± SEM. Statistical analysis was 
performed by Prism software (GraphPad) using the Wilcoxon test. P< 0.05 was 
considered statistically significant.  
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4. RESULTS 
 
Size and surface marker characterization of MSC-derived EVs 
To characterize MSC-derived EVs, we first analyzed their size using dynamic 
light scattering (DLS). We identified two separate, equally represented 
populations of EVs derived from resting MSCs (Fig 1 A). The small-sized EVs, 
ranging from 30 to 100 nm (peak 40.43 ± 15.63 nm, percentage 46.6%), 
corresponded to exosomes. The large-sized population of EVs, ranging from 100 
to 400 nm (peak 207.7 ± 53.95 nm, percentage 53.4%), corresponded to 
microvesicles. The percentage of exosomes was significantly higher as compared 
to microvesicles in EVs derived from primed MSCs (75.1% and 24.9%, 
respectively) (Fig. 1 B). Furthermore, we re-analyzed the size of EVs after 
freezing and thawing the samples. We observed the same DLS profile, 
demonstrating that EVs maintained their integrity (Fig. 1, C and D). To assess the 
surface marker profile of MSC-derived EVs, we used a multiplex bead-based 
platform that allows the detection of 37 surface epitopes. Both resting and primed-
EVs were positive for the well-established exosome markers CD63, CD81 and 
CD9 (Fig. 1 E). In particular, CD63 intensity was higher compared to CD81 and 
CD9 expression. As the cells of origin, MSC-derived EVs were positive for 
CD29, CD44, CD105 and negative for hematopoietic, epithelial, and cancer stem 
cell markers (Fig. 1 F). Moreover, MSC-derived EVs expressed SSEA-4 (Fig. 1 
F), an early embryonic glycolipid antigen identifying the adult MSC population 
derived from BM (97). Furthermore, we found a significant expression of CD146 
(Fig. 1 F), a typical molecule characterizing a specific subpopulation of MSCs 
with a higher therapeutic potential (98). Western blot analysis confirmed the 
surface marker profile of EVs, as far as the exosome marker CD63 and the 
hMSC-associated markers CD44, CD105, and CD146 are concerned (Fig. 1 G).   
 
MSC-derived EV internalization by activated B lymphocytes 
To evaluate a possible role of MSC-derived EVs in modulating B cell activity, we 
first assessed the potential of MSCs to transfer membrane fragments and RNA 
molecules to activated B lymphocytes. To this aim, activated B lymphocytes were 
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co-cultured with resting or primed MSCs labelled or not at membrane (Vibrant 
Dil) and RNA (Syto RNA Select) level with fluorescent probes. The transfer of 
MSC-derived membrane and RNA was observed at different culture times by 
flow cytometry. At each time points we observed a higher internalization of cEVs 
compared to pEVs (Fig. 2 A). The same trend was observed considering 
separately the internalization of MSC-derived membranes and RNA molecules, 
with a more marked effect on RNA transfer (Fig. 2, B and C). We detected a 
double-positive B cell population receiving MSC-derived EVs containing RNA 
(Fig. 2 D). EVs derived from both resting and primed MSCs were internalized by 
activated B lymphocytes. Initial incorporation was observed after 24 hours of co-
culture, followed by an increase until 72 hours. These observations suggest a 
possible transfer of EVs devoid of RNA molecules or, alternatively, a rapid 
degradation of MSC-derived RNA molecules by activated B lymphocytes. To 
confirm EV internalization, we directly co-cultured activated B cells with double-
labelled resting or primed EVs and the incorporation was assessed by 
fluorescence microscopy (Fig. 2 E). Overall, our data showed that the uptake of 
MSC-derived EVs occurs at both resting and primed conditions, thus highlighting 
a possible involvement of EVs in modulating B cell activity. 
 
Proteomic profiling of MSCs and EVs 
To identify proteins potentially involved in immunomodulatory properties 
mediated by pEVs, MSCs treated or not with inflammatory stimuli and 
corresponding EVs were analyzed using shotgun MS. A complete list of the 
identified proteins is shown in Supplementary information, Table S1 (external 
file). As expected, the number of identified proteins in the cells is higher 
compared to that identified in the EV compartment (Supplementary 
information, Figure S1, A and C). Nevertheless, the number of modulated 
proteins is similar among the two compartments (Supplementary information, 
Figure S1 B and Table S2).  
To assess the overall variation of the samples following inflammatory stimuli, 
shotgun MS data were processed by PCA. The score plot of the first two PCs 
calculated for EVs (Fig. 3 A) and MSCs (Fig. 3 B) allows the clear separation of 
 24 
 
the sample groups, thus indicating that the information about the inflammatory 
stimuli is present in the protein profile of both EVs and MSCs samples; 
nevertheless, in the case of EVs, two samples (BM004 and D24) seem quite 
different as they are far from the others located at the origin of the axes.  
We analyzed differentially expressed proteins in pEVs and pMSCs using both 
univariate and multivariate approaches. By using the univariate analysis, we found 
55 and 39 proteins differentially expressed in pEVs and in pMSCs, respectively 
(Supplementary information, Table S3, external file). Using the multivariate 
approach, based on Ranking-PCA followed by PLS-DA, we found 181 and 363 
proteins differentially expressed in pEVs and in pMSCs, respectively, considering 
1 PC in Ranking-PCA and 1 LV in the final PLS-DA models (for MSCs, only the 
first 200 proteins selected by Ranking-PCA were included in the PLS-DA model). 
Fig. 3 C and D report the score plots of the first 2 LVs for EVs and MSCs, 
respectively. Selected proteins clearly separate resting from primed samples 
(BM0004 and D24 EVs samples are no more separated from the others as in PCA 
analysis). The obtained models allowed the perfect classification of all the 
replications of all the samples (NER% = 100%, accuracy = 100%), both in fitting 
and in cross-validation for both EVs and MSCs. The list of candidate biomarkers 
identified by multivariate analysis and the corresponding regression coefficients 
are provided in Supplementary information, Table S4 (external file). Variables 
with a positive coefficient correspond to up-regulated proteins, while those 
characterized by a negative coefficient correspond to down-regulated proteins. 
The variables can be ordered according to a decreasing discrimination ability on 
the basis of the decreasing absolute value of the regression coefficient. The 
multivariate models were compared to PLS-DA models built including the 
markers identified as statistically significant by classical univariate statistics (Fig. 
3, E and F) and provided the same classification performances (100% in fitting 
and cross-validation for all the samples). 
For downstream analyses, we selected significantly modulated proteins obtained 
using both univariate and multivariate approaches: thus, we found 51 (Fig. 4 A) 
and 39 (Fig. 4 B) modulated proteins in pEVs and pMSC respectively. Notably, 
AAAT, CO1A1, CO1A2, COCA1, FINC and ICAM1 were the 6 proteins 
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modulated both in pMSCs and pEVs showing the same trend (Fig. 4 C). 
Interestingly, among modulated proteins in pEVs, we found a strong down-
regulation of different proteins involved in many processes related to the immune 
response, such as LG3BP (galectin-3-binding protein), PTX3 (pentraxin 3), CCL5 
(C-C motif chemokine 5), ENOA (alpha-enolase), MOES (moesin), and S10A6 
(Protein S100-A6). To confirm the results obtained through shotgun MS, we 
selected 4 proteins according to their immunomodulatory potential and we 
validated their expression through western blotting. As expected, Galectin-3-
binding protein (LG3BP) and pentraxin 3 (PTX3) were up-regulated, while 
moesin (MOES) and Protein S100-A6 (S10A6) were down-regulated in pEVs 
compared to cEVs (Fig. 4 D).  
 
Protein annotation and Pathway Enrichment Analysis on modulated proteins 
Differentially expressed proteins of pEVs and pMSCs were annotated on the basis 
of the GO terms. Considering the pEVs dataset, we found 20 GO terms 
significantly enriched in the ‘cellular component’ category (Fig. 5 A), most of 
which are related to exosomes and EVs, and 11 and 14 terms enriched in 
‘molecular function’ and ‘biological process’ categories, respectively 
(Supplementary information, Figure S2, A and C). As for the enriched GO 
terms of differentially expressed proteins in pMSCs, we found only 4 GO terms in 
the ‘cellular component’ (Fig. 5 B), of which the most significant was 
‘extracellular exosome’, only one term in ‘molecular function’ category and 10 
enriched terms in ‘biological process’ category (Supplementary information, 
Figure S2, B and D). As expected, many terms refer to biological processes 
related to the immune system and response to inflammatory stimuli.  
To identify potentially perturbed molecular pathways, pEV-derived modulated 
proteins were mapped to terms in the KEGG database and categorized into 35 
pathways significantly enriched (adjusted p-value < 0.05) (Fig. 5, C and E). 
Notably, the top 10 pathways included the following terms: (i) ‘PI3K-AKT 
signaling pathway’, an important pathway involved in cell proliferation, survival 
and growth; (ii) ‘regulation of actin cytoskeleton’; (iii) ‘focal adhesion’; and (iv) 
‘leukocyte trans-endothelial migration’. These pathways are crucial during 
 26 
 
leukocyte activation, especially during leukocyte migration through activated 
venular walls. Pathway enrichment analysis was also performed for deregulated 
proteins of pMSCs and 8 pathways resulted significantly enriched (Fig. 5, D and 
F). Modulated proteins resulting enriched in these four KEGG pathways were 
mainly down-regulated (Fig. 5 G), thus suggesting a possible inhibition of these 
pathways in immune effector cells, mediated by pEVs.  
 
pEVs induce a down-regulation of PI3K-AKT signaling pathway in activated 
B lymphocytes  
To evaluate the capability of MSC-derived EVs to modulate the PI3K-AKT 
signaling pathway, activated B lymphocytes were treated with cEVs or pEVs. The 
expression and phosphorylation profile of different components of PI3K-AKT 
signaling pathway (PAN AKT, AKT pS473, GSK3b pS9, p70S6K, S6 pS240, S6 
pS235pS236) was evaluated by flow cytometry. We observed a strong up-
regulation of the pathway during B cell activation, especially considering the 
phosphorylation of the ribosomal protein S6, one of the main PI3K-AKT 
downstream effectors (Fig. 6 A). As expected, the treatment with pEVs induced a 
significant down-modulation of the pathway compared to cEVs (Fig. 6 B). We 
observed a significant reduction of S6 pS235pS236 when activated B 
lymphocytes were cultured with both cEVs and pEVs. However, the treatment 
with pEVs led to a significantly higher reduction compared to the treatment with 
cEVs. 
 
MSC-derived EVs inhibit B cell spreading 
The second most significant KEGG pathway enriched in EV-modulated proteins 
was ‘regulation of actin cytoskeleton’. Many works revealed that B cells undergo 
dramatic morphological reorganization following antigen-mediated activation (99-
101). In these mechanisms, the activation of actin cytoskeleton seems to play a 
crucial role, especially during early events on B cell activation (100). To test the 
possible role of MSC-derived EVs to promote the reorganization of B cell actin 
cytoskeleton, we evaluated the ability of B lymphocytes, either pre-treated or not 
with MSC-derived EVs, to spread on coverslips coated with immobilized F(ab’)2 
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anti-human IgM/IgA/IgG (102). We first verified the specificity of F(ab’)2 anti-
human IgM/IgA/IgG to induce cell spreading (Fig. 7, A and B). The percentage 
of cell spreading after one hour of incubation on coated coverslip was 55%. 
Spreading cells showed elongated and irregular shape with an average area of 129 
± 59 µm2 (Fig. 7 B). B lymphocytes pre-treated with pEVs showed a significantly 
reduced cell spreading, with a cell area average of 111 ± 61 µm2, as compared to 
the one treated with cEVs, with a cell area average of 86 ± 41 µm2 (Fig. 7 C). In 
addition, the treatment with cEVs lowered the percentage of spreading cells to 
47%, while spreading cells were strongly reduced to 27% when B lymphocytes 
were treated with pEVs (Fig. 7 D) We also observed differences in terms of cell 
shape in the different experimental conditions. While the morphology of 
spreading B cells treated with cEVs was similar to the one of the control 
condition, pEVs induced B cells to retain a spherical shape (Fig. 7 E). These 
results confirmed the potential of MSC-derived EVs to modulate the organization 
of actin cytoskeleton by inhibiting its activation during the processes of B cell 
spreading. This observation suggests another possible mechanism of action 
explaining the immunomodulatory properties mediated by MSC-derived EVs, in 
addition to the modulation of PI3K-AKT signaling pathway. 
 
miRNA expression profile of MSCs and EVs 
To determine miRNA expression pattern in MSCs and EVs following the 
treatment with inflammatory stimuli, we performed next generation miRNA 
sequencing. To evaluate the overall variation of the samples, miRNA sequencing 
data were analyzed by PCA (Fig. 8, A and B). PCA revealed a clear separation 
between cMSCs and pMSCc, while cEVs and pEVs were not clearly separated. 
The same trend was observed using the hierarchical clustering analysis (HCA) 
among the 9 samples in terms of significantly differentially expressed miRNAs 
between cMSCs and pMSCs and corresponding EVs (Fig. 8, C and D). Cellular 
samples were completely divided into two branches, corresponding to the treated 
and the control groups, while cEVs and pEVs were not well separated. These 
observations highlight that the impact of inflammatory stimuli on miRNA 
expression is much more evident in MSCs rather than in EVs. Following the 
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treatment with inflammatory stimuli, we found 15 miRNAs differentially 
expressed in pEVs (Fig. 8 E), of which 4 up- and 11 down-regulated. Some of 
them are known to be involved in different immunological responses. In the 
cellular compartment we found 46 miRNAs differentially expressed between 
cMSCs and pMSCs (Fig. 8 F). Three miRNAs resulted modulated with the same 
trend both in pMSCs and pEVs, i.e. miR-155-5p, miR-199a-5p and miR-222-3p 
(Fig. 8 G). 
To assess the functional role of specific miRNAs in MSC-derived EV 
immunomodulatory properties towards B lymphocytes, we selected miRNAs for 
RT-qPCR validation by evaluating their experimentally validated targets 
(Supplementary information, Table S5) that were mapped to the terms in the 
KEGG database. Eventually, miRNA-155-5p, miRNA-199a-5p, and miRNA-497-
5p resulted the most promising miRNAs. Supplementary Table S6 shows the top 
20 pathways significantly enriched (adjusted p-value < 0.05) for each miRNA. 
Notably, these miRNAs can modulate the PI3K-AKT signaling pathway, one of 
the pathway that we found impaired following the treatment with MSC-derived 
EVs. To confirm the results of miRNA-Sequencing, the expression of miRNA-
155-5p, miRNA-199a-5p, and miRNA-497-5p was validated through RT-qPCR 
(Fig. 8 H). 
 
miR-155-5p reduce B cell viability and PI3K-AKT signaling pathway 
Due to its strong up-regulation in pEVs and its potential role in 
immunomodulation processes, we investigated the effect of miR-155-5p on B cell 
activity. Although the over-expression of miR-155-5p in activated B lymphocytes 
did not affect cell proliferation (data not shown), we observed a significant 
reduction in cell viability (Fig. 9 A). Furthermore, considering that many genes 
belonging to PI3K-AKT signaling pathway are targeted by miR-155-5p, we 
assessed its contribution on PI3K-AKT pathway activation. As expected, miR-
155-5p contributed to reduce PAN AKT expression and ribosomal protein S6 
phosphorylations (Fig. 9 B).  
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miRNA targets annotation and Pathway Enrichment Analysis 
As the identification of miRNA targets can provide insights into the biological 
role of differentially expressed miRNA in pEVs and pMSCs, we used 
miRTarBase, a resource for experimentally validated microRNA-target 
interactions, to identify the list of experimentally validated miRNA targets (data 
not shown). To determine their functions, the targets of the top 10 miRNAs 
modulated in pEVs and pMSCs were annotated on the basis of the GO terms. 
Supplementary Figures S3 A and B show the top 10 GO terms significantly 
enriched in the ‘cellular component’, considering EVs and MSCs compartments, 
respectively. Interestingly, the enrichment profile resulted almost equal into the 
two compartments. A similar trend occurred also considering ‘molecular function’ 
and ‘biological process’ categories (Supplementary information, Figure S3 C 
and D). These observations suggest that probably miRNAs modulated in pEVs 
only reflected the state of miRNA expression profile of the cell of origin. Many 
terms that we found in the three GO categories were related to the transcription 
activity, such as ‘gene expression’, ‘RNA binding’, ‘transcription factor binding’, 
and ‘transcription coactivator activity’. Thus, we could expect that the genes 
targeted by modulated miRNA in pEVs are involved in the regulation of the 
transcriptional activity of target cells. Concerning the enriched pathways, 
Supplementary Figure S3 G shows the top 10 KEGG pathways that could be 
affected by modulated miRNA in pEVs. We observed a strong enrichment of 
pathways related to cancer, highlighting a potential role of MSC-derived EVs in 
mediating cancer-related processes. Moreover, we found the following terms 
already identified with enrichment analysis on modulated proteins: (i) ‘focal 
adhesion’, and (ii) ‘regulation of actin cytoskeleton’. Thus, the modulation of 
specific proteins together with the modulation of specific miRNA in pEVs could 
affect the activity of B lymphocytes, especially during leukocyte migration. 
 
Combination of miRNA and proteomic profiles of MSCs and EVs 
To verify possible correlations between miRNA and proteomic profiles, the data 
from miRNA expression profiles and proteomic determinations were merged by 
using a multivariate approach. To perform this operation, only the individuals in 
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common with both characterizations were retained; therefore, 4 samples were 
considered. Only proteins expressed in at least 2 individuals over 4 were 
considered. Due to the small number of samples involved, only PCA results are 
presented; however, to show only the correlation structure of the most 
discriminating variables, PCA was carried out on the first 200 variables selected 
by ranking-PCA as the most discriminating for both EVs and MSCs. The score 
plot of the first two PCs calculated for EVs (Fig. 10 A) and MSCs (Fig. 10 B) 
allows the clear separation of the groups of samples.  
Looking at the loadings for EVs (Supplementary information, Table S7), it is 
possible to verify that Ranking-PCA first includes mainly miRNA signals (and a 
lower number of proteins), while the last half of the added signals belongs to the 
proteomic group. Similar considerations can be drawn from the loadings in the 
case of MSCs (Supplementary information, Table S7); however, in this case 
Ranking-PCA includes almost exclusively miRNA signals in the first 200 
variables and just a few proteins, thus indicating that in the case of MSCs the two 
characterization profiles are more independent from each other. Positive 
coefficients correspond to variables (miRNAs or proteins) over-expressed in 
primed samples, while variables with negative coefficients have the opposite 
behaviour. The loadings show a strong correlation between miRNA profiles and 
proteomic signals.   
 
miRNAs differentially expressed in pEVs modulate pathways affected by 
pEV proteins  
To verify other correlations between miRNA and proteomic profiles, we 
employed an in-silico approach to evaluate the possible involvement of miRNAs, 
differentially expressed in pEVs, in regulating some of the top enriched pathways 
affected by modulated proteins. We correlated miRNA-Seq and shotgun MS 
results. To this aim, we evaluated the percentage of genes belonging to ‘PI3K-
AKT signaling pathway’, ‘regulation of actin cytoskeleton’, ‘focal adhesion’, and 
‘leukocyte trans-endothelial migration’ KEGG pathways targeted by miRNAs 
differentially expressed in pEVs. All 15 differentially expressed miRNAs targeted 
more than 50% of genes that constitute ‘PI3K-AKT signaling pathway’ and 
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‘regulation of actin cytoskeleton’ pathways (61.8% and 52.8%, respectively) (Fig. 
10, C and D). Moreover, 14 miRNAs targeted 58% and 72.4% of genes 
belonging to ‘leukocyte trans-endothelial migration’ and ‘focal adhesion’ 
pathways, respectively (Fig. 10, E and F).  
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5. DISCUSSION AND CONCLUSIONS 
 
EV-mediated cellular communication has become a hot research topic because of 
increasing evidence of EV involvement in many physiological and pathological 
conditions. Depending on their molecular composition, EVs can influence several 
biological processes by directly activating cell surface receptors and delivering 
molecular effectors into target cells (11-13). The molecular composition of EVs is 
strictly influenced by the cell of origin and different environmental conditions; 
accordingly, EVs secreted by different cell types can modulate the immune 
system depending on such molecular composition (1, 4, 18, 44). 
The predominance of paracrine mechanisms in MSC-mediated 
immunomodulatory effect has been broadly demonstrated (103-106). These 
mechanisms include the release of EVs responsible for the reduction of immune 
effector cell activation, especially as far as B and NK cells are considered (45). 
MSC priming with inflammatory cytokines dramatically enhances their 
immunosuppressive properties, thus increasing the capability of EVs they release 
to reduce the immune responses (45). Many studies have confirmed the beneficial 
effect of MSC-derived EVs in vivo, paving the way for alternative cell-free 
therapeutic approaches in the field of inflammatory and autoimmune diseases 
(107, 108). Nevertheless, the therapeutic application of MSC-derived EVs is still 
hampered by the lack of standardized and reproducible methods of EV isolation, 
characterization and quantification and by the difficulty of large-scale production 
of EVs for therapeutic purposes. In addition, considering their involvement in 
several physiological and pathological processes, further pre-clinical studies are 
necessary to exclude possible adverse or simply undesirable effects of MSC-
derived EVs. For this reason, a comprehensive analysis of MSC-derived EVs 
allows to understand the molecular mechanisms underlying their 
immunomodulatory properties, thus identifying novel therapeutic targets as safer 
and more useful alternatives to cell or EV-based therapeutic approaches.  
On the other hand, the role and prognostic significance of EVs have been 
documented in a broad range of hematological malignancies, including B-cell 
leukemia and lymphoma, with a clear involvement in the development and 
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progression of the disease (77-79). In all these pathological conditions, BM 
stromal cells represent a pivotal player in the survival, proliferation, 
differentiation and chemoresistance of neoplastic B cells (109, 110). 
Consequently, in this work we focused the analysis on the crosstalk between 
MSCs and B cells, as we have recently shown that pMSC-derived EVs strongly 
modulate B cell activity. Here, we showed the effect of inflammatory stimuli on 
MSC-derived EV secretion and content in terms of miRNA and protein 
expression profile. We also correlated EVs content with their immunomodulatory 
properties towards B lymphocytes.  
Notably, inflammatory priming induced MSCs to release a higher percentage of 
exosomes compared to microvesicles, suggesting that the role of smaller vesicles 
could be functionally more crucial in mediating MSC-related immunosuppressive 
mechanisms. As shown by flow cytometry, the internalization of cEVs by B 
lymphocytes resulted higher than pEVs, probably due to the different size of EVs 
released by MSCs in normal or inflammatory conditions. Inflammatory stimuli 
affected not only MSC-derived EV size, but also their protein and miRNA 
content. Protein expression profile of MSCs and MSC-derived EVs was deeply 
affected by inflammatory priming. Interestingly, modulated proteins in cellular 
compartment were mostly involved in the release of extracellular exosomes, thus 
highlighting the significance of EV release by MSCs during inflammatory 
processes and, consequently, their role in MSC-mediated immune regulation. 
Furthermore, modulated proteins in pEVs are involved in different processes 
related to immunological events, especially during leukocyte activation and 
migration. Such processes include ‘PI3K-AKT signaling pathway’ and ‘regulation 
of actin cytoskeleton’. PI3K-AKT signaling pathway is an intracellular pathway 
affecting the function of several biological processes, such as cell survival, cell 
cycle progression, and cellular growth (111), while the regulation of actin 
cytoskeleton is pivotal during leukocyte activation, especially during the early 
stage of B cell receptor activation (99). The proteins belonging to these pathways 
resulted down-modulated, thus suggesting their possible involvement during the 
process of immunosuppression towards effector cells. As expected, pEVs induced 
a strong down-modulation of PI3K-AKT components and a substantial 
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impairment of actin reorganization in B lymphocytes during the early stages of 
activation. These results confirmed the ability of pEVs to modulate essential 
processes during the immune response mediated by B lymphocytes and suggest 
some of the potential mechanisms of action underlying the immunomodulatory 
properties mediated by MSC-derived EVs. Pathway enrichment analysis for 
modulated proteins in pMSCs revealed only four terms, including ‘antigen 
processing and presentation’ pathway as significantly enriched, highlighting the 
well-known capacity of MSCs to present antigen via major histocompatibility 
complex (MHC) molecules, which are constitutively expressed and up-regulated 
on MSCs following inflammatory priming (45, 112). Similarly, only the term 
‘identical protein binding’ resulted significantly enriched in the molecular 
function GO category. Taken together, our results showed that inflammatory 
stimuli mainly affect the protein content of EVs compared to the originating cells, 
confirming their crucial role and the predominance of paracrine mechanisms in 
mediating immunomodulatory functions. Focusing on modulated protein in pEVs, 
we found several proteins involved in many processes related to immune 
response, such as LG3BP, PTX3, MOES, and S10A6. Galectins are a family of 
beta-galactoside-binding proteins implicated in modulating cell-cell and cell-
matrix interactions. LG3BP promotes integrin-mediated cell adhesion and 
influences different processes of immune response, such as NK cell activation and 
lymphokine-activated killer (LAK) cell cytotoxicity (113). PTX3 is involved in 
the regulation of innate resistance to pathogens and inflammatory reactions. The 
expression of this protein is induced by inflammatory cytokines in several 
mesenchymal and epithelial cell types (114). MOES and S10A6 are also involved 
in immune response mechanisms, especially regarding the organization of actin 
cytoskeleton and cell motility (115-117). Considering their function, each of such 
modulated protein could contribute to immune regulatory activity mediated by 
MSC-derived EVs. In addition, pEVs showed a strong up-regulation of ITI 
components. ITI represents a family of structurally related plasma serine protease 
inhibitors involved in extracellular matrix stabilization (118). Frequent loss of 
expression of ITIH genes is recurring in multiple human solid tumors, thus 
promoting tumor metastasis (119). This observation further strengthens the role of 
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MSC-derived EVs in cancer, with a potential therapeutic action in preventing 
tumor metastasis. 
Inflammatory microenvironment affected not only MSC-derived EVs proteins, 
but also miRNA expression. In consideration of miRNA stability and involvement 
in modulating gene expression, their role in cell-to-cell communication mediated 
by EVs has been increasingly studied in the last years. As for miRNA overall 
variation following inflammatory priming, enriched GO terms resulted similar in 
pMSCs and pEVs, showing less remarkable differences between cellular and EV 
compartment in miRNA composition as compared to proteins composition. 
Modulated miRNAs influence many processes related to transcription activity; 
accordingly, pathway enrichment analysis showed a strong enrichment of 
pathways related to cancer in both dataset. On the other hand, there is a clear 
evidence that MSCs and MSC-derived EVs can enhance or suppress tumor 
progression depending on tumor model and stage considered (71, 120, 121). 
Nevertheless, differentially expressed miRNAs in pEVs are also involved in 
immunomodulatory processes. Among these, we identified ‘focal adhesion’ and 
‘regulation of actin cytoskeleton’ KEGG pathways, already found amongst 
modulated proteins. Thus, the modulation of specific proteins together with the 
modulation of specific miRNAs in pEVs could affect the activity of immune 
effector cells, especially during leukocyte migration. 
Protein and miRNA molecules contained in MSC-derived EVs following 
inflammatory priming are strictly connected. They could be transferred into target 
cells and contribute synergistically to the regulation of immune effector cell 
activity. Notably, we found that all differentially expressed miRNAs in pEVs 
influence the most significant enriched pathways resulting from the protein 
differential expression analysis. Furthermore, many of them have a crucial role in 
immunological processes in different cellular contexts (122). In particular, 
miRNA-155-5p is one of the most well characterized miRNA regulating immune 
response (123-125). Here, we showed that miRNA-155-5p has a direct capability 
to reduce cell viability in activated B lymphocytes. This effect could be in part 
mediated by its ability to act as negative regulator of PI3K/AKT signalling 
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pathway, one of the pathway we proved to be impaired following the treatment 
with MSC-derived EVs. 
In summary, our data show that MSC-derived EVs contain several molecules 
potentially responsible for their immunomodulatory properties and MSC/B-cell 
crosstalk; in particular, specific molecules modulated in pEVs are capable of 
influencing immune effector cell activity, especially considering B-cell response, 
thus representing novel potential therapeutic targets that could be further 
investigated in the field of inflammatory and autoimmune diseases as well as in 
neoplastic microenvironment of B-cell malignancies.  
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Fig.1 Size and surface marker characterization of MSC-derived EVs. Histograms 
represent hydrodynamic diameter distribution plots measured on EVs freshly isolated 
from resting (A) and primed MSC (B) (cEVs exosomes peak 40.43 ± 15.63 nm, 
percentage 46.6%; cEVs microvesicles peak 207,7 ± 53,95 nm, percentage 53,4%; pEVs 
exosomes peak 51,17 ± 23,23 nm, percentage 75,1%; pEVs microvesicles peak 200,9 ± 
63,57 nm, percentage 24,9%). (C) Hydrodynamic diameter distribution of cEV stored at -
80°C (cEVs exosomes peak 51,08 ± 21,07 nm, percentage 59%; cEVs microvesicles peak 
196,9 ± 65,34 nm, percentage 41%). (D) Hydrodynamic diameter distribution of pEV 
stored at -80°C (pEVs exosomes peak 55,91 ± 21,99 nm, percentage 83,6%; pEVs 
microvesicles peak 201,1 ± 76,45 nm, percentage 16,4%). Error bars represent mean ± 
SD obtained from at least five measurements of three independent samples. All 
experiments were performed in PBS at 25° C. (E) Background corrected median 
fluorescence intensity of CD9, CD63, CD81 markers and corresponding isotype controls 
on cEVs and pEVs (n=5). (F) Background corrected median fluorescence intensity of 34 
surface epitopes on cEVs and pEVs (n=5). (G) Immunoblot analysis of CD44, CD146, 
CD105 and CD63 expression in cEVs and pEVs. This blot is representative of three 
independent experiments showing the same trends. 
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Fig. 2 Incorporation of MSC-EVs and RNA transfer in activated B lymphocytes. (A) 
Percentage of Vibrant Dil+ Syto RNA Select+ B cells co-cultured for 24, 48 and 72h with 
double stained resting or primed MSCs (n=5) *p<0.05. (B) Vybrant DiI (membrane 
staining) Geometric Mean of Fluorescence Intensity (GMFI) of B cells co-cultured with 
double stained resting or primed MSCs. (C) Syto RNA Select (RNA staining) GMFI of B 
cells co-cultured with double stained resting or primed MSCs. (D) Representative FACS 
analysis of Vibrant DiI+ Syto RNA Select+ B cells co-cultured for 48h with double stained 
(right) or not (left) resting or primed MSCs. (E) MSC-EVs were double-stained for 
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F 
membrane in red (Vybrant DiI) and for RNA in green (Syto RNA Select). Labeled EVs 
were incubated for 24h on activated B lymphocytes. The four panels show (from the left 
to the right) B cells stained with DAPI (blue), the internalization of membrane 
components of cEVs and pEVs (red), the distribution of Syto RNA Select carried by 
MSC-EVs inside B cells (green), and a merge between the three previous panels (original 
magnification 400x). The images are representative for three independent experiments 
with similar results. 
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Fig. 3 Overall variation of differentially expresses proteins in MSCs and EVs 
following inflammatory priming and PLS-DA. Score plot of the first two PCs 
calculated after the application of PCA to EVs (A) and MSCs (B). Score plot of the first 
two LVs calculated after the application of PLS-DA to the 181 proteins selected by 
Ranking-PCA on the EVs dataset (C) and on the first 200 proteins selected by Ranking-
PCA on the MSCs dataset (D). Score plot of the first two LVs calculated after the 
application of PLS-DA to the 55 proteins selected by univariate statistics on the EVs 
dataset (E) and on the 39 proteins selected by univariate statistics on the MSCs dataset 
(F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4 
 53 
 
E F 
G 
PI
3K
-A
K
T 
si
gn
al
in
g 
pa
th
w
ay
R
eg
ul
at
io
n 
of
 a
ct
in
 c
yt
os
ke
le
to
n
Fo
ca
l a
dh
es
io
n
Le
uk
oc
yt
e 
tra
ns
ed
ot
he
lia
l m
ig
ra
tio
n
0
5
10
15
up-regulated proteins
down-regulated proteins
N
u
m
b
e
r 
o
f 
p
ro
te
in
s
A 
C 
B 
D 
Fig. 4 Proteomic profile of resting and primed MSCs and corresponding EVs. (A) 
Differentially expressed proteins in pEVs compared to cEVs obtained both from 
univariate and multivariate approach (adj p<0.05, Fold Change (FC)>1.5 and FC<0.667) 
(n=7). (B) Differentially expressed proteins in pMSCs compared to cMSCs obtained both 
from univariate and multivariate approach (adj p<0.05, FC>1.5 and FC<0.667) (n=7). (C) 
Venn diagram representing modulated proteins both in pMSCs and pEVs. (D) 
Immunoblot analysis of LG3BP, MOES, PTX3 and S10A6 expression in cEVs and 
pEVs. This blot is representative of three independent experiments showing the same 
trends. 
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Fig. 5 GO protein annotation and Pathway Enrichment Analysis. Cellular component 
GO category annotation of differentially expressed proteins in pEVs (A, the top 10 terms 
are shown) and pMSCs (B). Pathway enrichment analysis on differentially expressed 
proteins in pEVs (C, the top 10 terms are shown) and pMSCs (D). Terms with adjusted p-
value<0.05 were considered significantly enriched. Cytoscape platform based 
ClueGO/CluePedia pathway analysis and visualization of differentially expressed 
proteins in pEVs (E) and pMSCs (F). Terms are grouped based on shared genes (kappa 
score) showed in different colors. The size of nodes indicates the degree of significance. 
The most significant term defines the name of the group. (G) Modulation of differentially 
expressed proteins in pEVs enriched in “PI3K-AKT signaling pathway”, “regulation of 
actin cytoskeleton”, “focal adhesion” and “leukocyte trans-endothelial migration” KEGG 
pathway (FC<0.0667 or FC>1.5, p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 PI3K-AKT signaling pathway expression in activated B lymphocytes co-
cultured with MSC-EVs. (A) Relative expression (fold change) of PAN AKT, AKT 
pS473, GSK3b pS9, p70S6K, S6 pS240, S6 pS235pS236 in activated B lymphocytes 
Fig. 6 
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analyzed by flow cytometry. (B) Relative expression (fold change) of PAN AKT, AKT 
pS473, GSK3b pS9, p70S6K, S6 pS240, S6 pS235pS236 in activated B lymphocytes 
treated or not with resting or primed EVs. Wilcoxon test *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 7 B cell spreading inhibition mediated by MSC-EVs. (A) Cell area of B cells 
plated on coverslips coated or not with F(ab’) 2 anti-human IgM/IgA/IgG (n=42 to 204). 
(B) Double-stained B cells with DAPI (blue) and rhodamine phalloidin (F-actin, red) 
before and after the induction of cell spreading (60 min). (C) Cell area of B cells pre-
treated with cEVs or pEVs and then plated on coated coverslips (n=212 to 398). (D) 
Percentage of spread B cells treated with cEVs or pEVs after 60 min of incubation on 
coated coverslips. (E) Double-stained B cells with DAPI (blue) and rhodamine phalloidin 
Fig. 7 
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(F-actin, red) after 60 min of incubation on coated coverslips. The images are 
representative for three independent experiments with similar results (Original 
magnification 400x). Error bars represent mean ± SEM of three independent experiments. 
T test *p<0.05, ***p<0.001. 
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Fig. 8 miRNA expression profile of MSCs and EVs following inflammatory priming. 
PCA plot calculated using regularized-logarithm transformation of miRNA counts on 
EVs (A) and MSCs (B) samples. Heatmap summarizing differentially expressed miRNAs 
in pEVs (C) and pMSCs (D). Bar plot representing the log2-fold change of differentially 
expressed miRNAs in pEVs (E) and pMSCs (F). (G) Venn diagram representing common 
differentially expressed miRNAs in pEVs and pMSCs. (H) RT-qPCR validation of 
differentially expressed miRNA in pEVs (n≥3). Wilcoxon test *p<0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9 Effect of miR-155-5p on B cell activity. (A) Relative cell viability of B cells 
transfected with double-stranded RNA mimic miR-155-5p (n=7). (B) Relative PI3K-AKT 
signaling pathway expression in B cells transfected with double-stranded RNA mimic 
miR-155-5p (n=5). Wilcoxon test *p<0.05. 
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Fig. 10 Combination of miRNA and proteomic profiles of MSCs and EVs. Score plot 
of the first two PCs calculated after the application of PCA to EVs (A) and MSCs (B). 
Chord diagrams representing proteins belonging to “PI3K-AKT signaling pathway” (C), 
“regulation of actin cytoskeleton” (D), “focal adhesion” (E), and “leukocyte trans-
endothelial migration” (F) KEGG pathways targeted by miRNAs differentially expressed 
in pEVs. 
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Supplementary information, Figure S1. Identified and modulated proteins in MSCs 
and EVs. (A) Number of identified proteins in resting and primed MSCs and 
corresponding vesicles (n=7). (B) Number of modulated proteins in pMSCs and pEVs 
compared to ctrl. Wilcoxon test **p<0.01. (C) Venn diagrams representing the number of 
common identified proteins in MSCs and EVs in resting condition for each donor 
analyzed. 
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Supplementary information, Figure S2. GO protein annotation. 
(A-B) Molecular function GO category annotation of differentially expressed proteins in 
pEVs (A, the top 10 terms are shown) and pMSCs (B). (C-D) Biological process GO 
category annotation of differentially expressed proteins in pEVs (C, the top 10 terms are 
shown) and pMSCs (D). Terms with adjusted p-value<0.05 were considered significantly 
enriched. 
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Supplementary information, Figure S3. Functional enrichment on miRNA targets. 
(A-D) Experimentally validated targets of the top 10 miRNAs differentially expressed in 
pEVs and pMSCs were mapped to terms in the GO database to get enrichment analyses in 
the “cellular component” (A-B, respectively), “biological process” (C-D, respectively), 
and “molecular function” (E-F, respectively) categories. (G-H) Pathway enrichment 
analysis on experimentally validated targets of the top 10 miRNAs differentially 
expressed in pEVs (G) and pMSCs (H). Terms with adjusted p-value<0.05 were 
considered significantly enriched. Panels show the top 10 enriched terms.  
 
A 
C 
B 
D 
E F 
G H 
 64 
 
Mesenchymal Stromal Cells 
 Identified proteins Modulated proteins (pMSCs vs cMSCs) 
 cMSCs pMSCs FC>1.5 FC<0.667 
D24 1154 951 69 46 
D21 663 857 60 33 
D8 757 807 47 49 
D29 821 829 64 111 
BM004 643 581 54 120 
D33 856 1136 179 77 
D36 1168 887 70 154 
     
Extracellular Vesicles 
 Identified proteins Modulated proteins (pEVs vs cEVs) 
 cEVs pEVs FC>1.5 FC<0.667 
D24 423 302 110 113 
D21 203 165 18 54 
D8 100 138 58 9 
D29 414 363 21 53 
BM004 230 216 49 78 
D33 432 281 46 172 
D36 392 282 23 115 
 
8. TABLES 
 
 
 
 
 
 
 
 
 
 
 
Supplementary information, Table S2. Identified and modulated proteins in resting and 
primed MSCs and corresponding EVs using shotgun MS. 
 
miRNA ID Experimentally validated miRNA targets 
hsa-miR-155-5p MEIS1,TAB2, MECP2, SOCS1, MSH6, MSH2, MLH1, INPP5D, DET1, SMAD5, 
HIVEP2, ZNF652, ZIC3, BACH1, JARID2, APC, WDFY1, VAMP3, UBE2J1, 
TXNRD1, TXNDC12, TRIP13, TRIM32, TRAM1, TNFRSF10A, TBCA, 
TACSTD2, SYPL1, SYNE2, SNAP29, SMAD1, SLC30A1, SH3BP4, SDCBP, 
SCAMP1, RHEB, RCOR1, RCN2, RAI14, RAB6A, RAB5C, RAB34, RAB27B, 
RAB23, PTPRJ, PRKCI, PRAF2, PPP5C, PPL, POLE4, POLE3, PODXL, 
PLXND1, PKN2, PICALM, PHC2, PDLIM5, PDE3A, NT5E, NARS, MYO1E, 
MYO10, MSI2, MPZL1, MOSPD2, MARC1, METTL7A, LY6K, LPL, UFL1, 
HSDL1, HSD17B12, GNA13, FMNL2, FADS1, DSG2, DPP7, DNAJC19, 
DNAJB1, DHX40, CYP51A1, CUL4B, CTNNB1, CLDN1, CHAF1A, CEBPB, 
CDK5RAP3, CBFB, BRPF3, BET1, ATP6V1C1, ATG3, ARL5B, ARL10, ARID2, 
ARFIP2, ARFIP1, ANKFY1, AMIGO2, TM6SF1, MATR3, LDOC1, JADE1, 
RHOA, AGTR1, TP53INP1, FGF7, IKBKE, NFATC2IP, CUX1, BCAT1, SPI1, 
CTLA4, EDN1, FOXO3, MAFB, TSHZ3, RUNX2, IFNGR1, ZNF236, LAT2, 
PAPOLA, EHD1, SERTAD2, PELI1, KBTBD2, HNRNPA3P1, SLC39A10, KRAS, 
CAMTA1, NAMPT, CREBRF, ETS1, TLE4, FAR1, EDEM3, TWF1, C3orf58, 
SLC25A40, PSMG1, IKBIP, LCLAT1, VEZF1, SACM1L, DCAF7, ERMP1, 
KRT80, FLI1, DOCK4, CYR61, ICAM1, SELE, SMAD2, MYB, SKI, WTH3DI, 
RNF123, CSF1R, SOX6, CKAP5, JUN, PKIA, CSNK1A1, GCSAM, KDM3A, 
UQCRFS1, IL13RA1, FADD, BCL6, MITF, MAP3K10, NOS3, UBR4, PAXX, 
MECR, LUC7L2, TCEA1, ANAPC16, C17orf80, SLC27A2, XPC, EIF3G, 
EIF2B5, UBA3, EIF3E, PCYOX1, EXOC7, QPCTL, DYNC2H1, GLIPR2, 
DNAAF5, UGT8, HSPB11, CCDC137, GLB1, LRRC40, VBP1, MGST2, GNB4, 
JUP, DNAJC2, GOLPH3, DRAP1, NOB1, SLC1A5, RAB14, YBX3, SLC39A14, 
UBE2J2, EIF4A1, CAB39L, MYLK, EIF2B2, CNDP2, RTN3, TMBIM6, EIF4G2, 
CDC42BPB, MYD88, ADH5, EIF3C, QRICH1, CYFIP1, PSIP1, SIN3A, STK24, 
AGL, METAP2, SPIN1, FAM98B, ERI1, COLGALT1, UGDH, LNPK, XPO1, 
PALLD, MUT, RAP1B, BAG5, LPGAT1, GCFC2, EXOSC2, LNX2, ZNF248, 
CHD9, MEF2A, CAB39, CLUAP1, CARD11, PCDH9, ZNF561, CARHSP1, 
C16orf62, LIN7C, CBR4, ECI1, OSBPL10, EIF4E2, TGM2, SLC9A3R2, 
CHAF1B, PPFIBP1, UBXN1, ESRRA, GAPVD1, MIA2, RBM42, MFF, NEU1, 
SCD, UBE2D2, OVCA2, EIF3CL, AURKA, P3H3, FUBP1, RETSAT, MPP2, 
KIAA0368, NES, KIF22, PACSIN2, SLC25A19, IPO8, GPT2, OGFOD1, 
AKR7A2, TRMT1, MCAM, INA, SNX6, PDAP1, PCNT, FIP1L1, MTAP, CEP55, 
 65 
 
AIFM1, PPM1G, PAM16, PLK1, AURKB, NASP, NUPL2, NCKAP1, EXOC2, 
SEC24B, RRM2, GRPEL1, ALDH9A1, AP1G1, LUZP1, RPRD1A, NAA25, RP2, 
NUP155, OTULIN, TMX3, ERGIC1, NFYC, UBE2D3, SUZ12, GLIPR1, GPM6B, 
LRIF1, TAF5L, HERC4, MORC3, MBNL3, UPF2, KRT6B, FLNA, DAG1, 
TIMM13, BUD31, CUTA, STIM1, EOGT, GEMIN5, GNPNAT1, STXBP2, PCCB, 
EIF3J, CHRAC1, PLAUR, CISD2, BCL7C, TICAM2, KDM1A, PSEN1, STRN, 
SMARCD2, RARS, RBPJ, LARS, ALDH1A2, CNOT10, UBE2H, TNKS1BP1, 
PUS7, RPL39, CTSA, MBLAC2, GAR1, RAD1, NOLC1, FGF2, KDELC2, 
HSPA4L, PEBP1, PNPLA4, GHITM, FAM3C, PGRMC2, RPAP1, NCAPG, 
PDE12, TFCP2, NKX3-1, L2HGDH, PRKAR2A, ARL5A, CD109, TOMM34, 
CFL2, AIMP1, MIDN, CDC73, TRIO, PAXBP1, TSPAN14, INTS6, YWHAZ, 
PRKAR1A, SSX2IP, FAM199X, RAC1, PLS1, SAP30L, MRPS27, TNFAIP2, 
JUNB, SPCS1, CTNNA1, ASNS, H2AFY, NR3C1, AXL, RING1, CLTA, 
COL4A2, CNNM3, CTNNBL1, CNOT9, ATL2, CDK5, PPP2R2A, THOC7, 
DNMT1, MRPL16, RAB6C, HAX1, ABHD16A, ASB6, GPAM, HDHD5, WDR11, 
NMD3, IGF2R, ACOT7, RRAGA, INTS7, YARS, FLNB, CORO1B, SUPT5H, 
KANK2, DIAPH3, FASTKD1, NSA2, FMNL3, CHTOP, STRBP, MARCKS, 
POLR1B, FNDC3B, CD3EAP, PSAT1, COPS3, DEGS1, OXCT1, PDK1, EIF3A, 
GMPS, OLR1, SMAD4, CD68, FLT1, CEP41, CIAPIN1, CCDC82, ACTR2, 
TRAK1, CYP2U1, SLC35F2, ZNF493, HAL, IL17RB, TBC1D14, ZNF254, 
GABARAPL1, JCHAIN, RAPGEF2, WBP1L, PBRM1, ABCC4, SPECC1, 
MAT2B, TFPI, EXOC3, PFDN4, HK2, TYSND1, C12orf10, CRAT, PLEKHA5, 
PACSIN3, F5, SMARCE1, CD81, VAV2, SLC7A1, OBSCN, MAVS, DMD, 
CARS2, SLC12A4, MRPS34, B4GALT1, KDELC1, PDCD10, NCAPD2, UBA2, 
ALDH5A1, FUBP3, MYO6, NAA50, MARC2, RIOK2, OSBPL9, DDX10, 
ATXN10, RAB30, DEK, PHF6, ARL8B, LEMD3, ZNF207, CSE1L, CPT1A, 
TTC37, MAN1A2, RICTOR, IMPAD1, VPS4B, CLINT1, UBQLN2, RIF1, PNPT1, 
MRPL18, MAP3K14, ARMC2, LCORL, APAF1, MPP5, RAB11FIP2, NOVA1, 
RBAK, ARL15, MYO1D, LRRC59, CMSS1, LONP2, MUS81, ITGB4, DDB2, 
CAT, ATPAF1, TPBG, INTS4, TIMM8A, RBM22, MTFMT, WRB, DDRGK1, 
GMPPA, EEF1A2, RDH13, CLTC, NOTCH2, CARS, PTMS, CSNK1A1L, 
LUC7L3, TJP1, FDFT1, CDKN2A, AKR1C3, PNPLA8, S100A11, IER3IP1, 
FSTL1, SLC38A5, ATP6V1H, ITGB5, SRSF2, SLC7A11, ANXA2, DDX17, 
RAB2A, FOXK1, TMOD3, PSME4, ZNF384, GNAS, SNTB2, TMTC3, SLC30A7, 
ASPH, INTS8, CPD, EGFR, SRPK2, STAG2, IRF2BP2, TPRKB, VPS36, 
VCAM1, SMAD3, TTF1, FAM91A1, CEP83, MARF1, CDC40, DCUN1D2, 
KLHL5, AGO4, HBP1, WWC1, WEE1, GOLT1B, PALD1, THBS1, DBN1, 
DHCR24, HSD17B7, NSUN5, TPP2, UAP1, OXNAD1, SSSCA1, EEF1E1, 
PHGDH, CCND1, ALDH3A2, CDK2, SGPL1, TSPAN3, ANPEP, PSME3, AGRN, 
GNL3L, VANGL1, RTFDC1, WNT5A, TMEM167A, CLIC4, MEST, TRIM24, 
CDH6, MMS22L, SKIV2L2, CCR9, DR1, RSF1, ANTXR1, SEPT11, HNRNPA3, 
CXCL8, ZNF83, PHF14, TBC1D8B, INPP5F, ARPC3, KRCC1, FAM177A1, 
UBTD2, SECISBP2, PAK2, SLC33A1, ZNF28, MCM8, SMARCA4, TCF12, 
TOMM20, UBQLN1, PDPR, MOV10, FAM120A, FAM96B, FKBP3, STAT3, 
NEUROG1, EPRS, CDH2, CDH13, ATP13A1, EIF3F, NUP62, GCLC, LSM3, 
HTRA1, CDK4, EPB41L2, COG2, CCT2, NUCKS1, PRSS21, INTS10, STX5, 
CIAO1, GLG1, TROVE2, ARGLU1, CALU, BRI3BP, RAD23B, PYGL, MRS2, 
KIF14, POLR2C, TPD52, MTHFD2, RNF2, LTN1, TMEM33, TNPO1, GSK3B, 
ADAM10, ERBIN, CCL2, NFKB1, IL6, CD36, RREB1, ZKSCAN5, ZNF611, 
ZNF273, PDCD4, VPS18, NSD3, MASTL, MYBL1, GATM, E2F2, FAM135A, 
C3orf18, ARL6IP5, SHANK2, SH3PXD2A, PIK3R1, VHL, PATJ, MMP16, FOS, 
MAPK14, RAPH1, RAB3B, KLF9, MYC, ITK, IL2, SEL1L, DOCK1, RAD51, 
THRB, TERF1, ZBTB18, ZNF431, ZBTB38, ZSWIM6, ADD3, S1PR1, CBL, 
AGTRAP, WNK1, KCTD3, KLHL42, SP1, CHURC1, MEX3C, TWSG1, ZNF492, 
CCNT2, PIK3CA, DMTF1, CHD7, DCAF10, DDX3Y, CSNK1G2, ZNF714, 
TADA2B, UBXN2B, ACOX1, ELK4, KCTD5, ANKRD12, HIF1A, ZNF148, 
NAA16, ETNK2, TRPS1, PEA15, PTN, MXI1, SOCS3, ZNF98, ZNF468, 
ZNF300, ZNF260, ZNF160, ZKSCAN1, YEATS2, XPNPEP1, WDR82, VCPIP1, 
USP8, UBE2G1, TTC8, NEMP1, TMEM123, TCF4, TAPT1, STRN3, SSU72, 
SSH2, SLC11A2, SIRT1, SRSF1, KMT5A, SERGEF, RPS20, RGL1, REV1, 
PTAR1, OSTM1, NFAT5, N4BP1, MKLN1, KPNA5, KIF3A, KCNN3, INPP5A, 
IFIT5, HMGCS1, HLA-DPA1, GANAB, GALC, SARAF, FGL2, FEZ2, EZH1, 
ENTPD1, DPY19L1, CREB3L2, CPEB4, CDC37, SWSAP1, BTBD1, AKAP10, 
ABI2, AAK1, CHD8, AKT1, PHACTR2, XPR1, RAB3IP, KIAA1841, PCCA, 
 66 
 
RHEBP1, UQCRB, FCAMR, SLC35A1, HHIP, SELENOT, CSRP2, CDKN1B, 
ZFP36, KANSL1, FITM2, CYP1A1, DENND1B, FAM76A, DOK2, ZNF703, 
SPRED1, TMEM136, CNOT6, ADAMTS4, MTRNR2L7, MTRNR2L5, PLEKHA2, 
RORA, ZNF678, UBL3, PRRC1, KLHL28, EEF2, ZNF644, MTRNR2L3, CDV3, 
MTRNR2L9, CHRDL1, ZNF500, TDRD6, MARVELD1, CNPPD1, FOXE1, 
TYRP1, MAPK13, SOCS6, RPTOR, TFAM, STAT1, CCND2, CASP3, TBRG1, 
HOMEZ, NR1H3, PTEN, FBXW7, SAMHD1, CS, GEN1, MTRNR2L1 
miR-497-5p RAF1, RUNX2, IGF1R, MAP2K1, EEF1A1, TCEA1, HIST1H3H, ALDH9A1, 
DESI2, HIST2H3A, PANK2, ATXN7L3B, BRD1, WEE1, DICER1, HDGF, BCL2, 
EIF4E, BIRC5, WNT7A, SMURF1, CHEK1, SHOC2, PLEKHA1, CEP55, 
ZDHHC16, CCND1, C1orf21, AMOTL1, CCND2, TARBP2, MTFR1L, USP15, 
FCF1, ARIH1, PAGR1, SNTB2, VPS4A, C16orf72, GOSR1, RPS6KB1, NAPG, 
GALNT1, CCNE1, PNPLA6, ZCCHC3, SOWAHC, UBR3, ZNRF3, YWHAH, 
B3GNT2, ACTR2, RARB, PI4K2B, CANX, E2F3, PPP1R11, HSPA1B, PIM1, 
VEGFA, CD2AP, CALU, UBN2, EN2, MAFK, FOXK1, USP42, DMTF1, ZFHX4, 
RAD23B, ZBTB34, RECK, ZNF275, OGT, LUZP1, CHAC1, SCAMP4, PAK2, 
ENTPD1, SKI, SPRED1, SMAD3, DCTN5, TNFSF9, RASSF2, ATP5G3, 
TNRC6B, GRAMD2B, CREBRF, PSAT1, PAFAH1B2, RPRD2, PNRC2, 
CDADC1, AGO4, GPR180, PPM1A, SLC39A9, FAM103A1, RBBP6, TAOK1, 
SNRPB2, HSPE1-MOB4, MOB4, BZW1, NUP50, FGF2, HSPA4L, RBPJ, 
TBPL1, FZD6, BAG4, ZNF449, YIPF6, MSL1, ELK4, GABARAPL1, ZNF691, 
DYNLL2, SRPRB, CDC42SE2, WIPI2, TBRG1, C1orf226, SETD1B, HOXC8, 
RAB3IP, PPP2R5C, SLCO3A1, CBX2, ZFP28, CHMP4B, GABPA, STRADB, 
MTMR3, CRIM1, SOCS5, CTDSPL, ITGA2, PIK3R1, PPIL1, CAPZA2, ZNRF2, 
OCRL, CHIC1, CRKL, BTRC, CDK4, CCND3, CDC25A, SIDT2, ASCC1, 
DMRT2, TLL1, LUC7L3, ALDH3B1, EFTUD2, CSNK1E, TPM2, ZNF460, 
FGFR4, DOCK11, ACTR3B, ZNF367, UBE2V1, UBE2Q1, TSC22D2, TOB2, 
TMEM189-UBE2V1, TMEM189, TM4SF1, TFAP2A, STK38, SSRP1, SIK1, 
SH3BP4, SEC24A, RNF168, REL, PISD, PDE4D, NR6A1, NFIC, NAA25, 
LAMC1, RUBCN, IVNS1ABP, IPPK, HOXA3, HEYL, GNB1, GNAL, FURIN, 
EIF1AX, DYRK3, CPSF7, CDK6, CARD10, AVL9, AKT3, AGO2, ABL2, ABHD2, 
ABCC6, PRKAR2A, VSIR, PHYHIP, CASKIN1, ZNRF1, CD180, KIAA0895, 
ORC4, ODF2L, DNAJA1, L2HGDH, ZNF622, ZMAT3, USP53, SYPL1, SRPRA, 
SREK1, SMAD7, PRICKLE2, LRIG2, KIF5B, FAM122B, E2F7, DDX3X, CDCA4, 
CDC37L1, ATG9A, ASGR2, ZNF620, HAUS3, YTHDC1, TMEM245, TMEM100, 
SRSF1, SNX16, SESTD1, RIMS3, RCAN3, PPIG, PLRG1, PLAG1, PHKA1, 
MYO5A, KIF23, HNRNPDL, CDK1, CCNE2, CBX6, AXIN2, CASK, DMPK, 
ATAD5, AKR1B10, GPATCH8, ARHGDIA, CPEB3, JARID2, CAMSAP1, 
ATG14, TRIM35, FLCN, NNT, SLC2A3, SBNO1, POM121C, NUFIP2, LAMP2, 
EFNB2, RPL14, GNAT1, HOXA10, CBX4, PHC3, PDCD1, BAZ2A, APP, 
ZNF585B, ANAPC13, PRSS21, RALGAPB, GSG1, POLDIP3, AP5Z1, CLSPN, 
UGT2B4, MAP4K2, CCDC83, DECR1, ZBTB10, YWHAQ, USP48, SALL1, 
RUNX1T1, RTN4, PNISR, PHLPP2, PAG1, NUCKS1, MKX, MBD4, LRRFIP2, 
KPNA3, KPNA1, HIGD1A, HCFC2, GRB2, FKBP1A, FBXL20, FASN, CRK, 
CLIP4, CDK17, CACUL1, C11orf24, ASH1L, AMOT, SLC29A1, OSCAR, 
MTHFR, FAM229B, EPM2AIP1, ZNF267, SSU72, DNAJC10, ZNF704, YRDC, 
TPM3, TMEM161B, TM7SF3, TAF13, SZRD1, RNF149, RACGAP1, RAB23, 
PTPRD, PRKAA1, PRDM4, PLPP3, LURAP1L, KANK1, HIST2H2BE, GPR27, 
EXT1, CYP26B1, CREBL2, CNKSR3, CA8, BTN3A3, ARHGAP12, OSBPL3, 
KRT33B, TUBB2A, MSANTD4, LANCL1, HNRNPA2B1, KIAA1456, SLC25A12, 
DLGAP3, THRAP3, SMDT1, RAPH1, CCNT1, ZNF391, CCDC80, ZBTB16, 
XKR7, WNK3, VAV2, TGFBR3, RASEF, NCKAP1, MAP3K7, KLHL15, GNG12, 
FZD9, CMTM4, CCDC88C, ARMC12, AHNAK2, ACVR2A, TLK1, UBE2H, 
TTLL5, RIF1, SERBP1, PHF19, LSM11, PLPBP, CLEC2D, PDIA6, N4BP1, 
TRAK1, ADRA2B, ANKMY1, GPRC5A, C3orf36, BSPRY, ANKRD36, KLHL40, 
NOTCH2, EIF2B2, CUL3, DCAF17, RS1, GLP2R, FLOT2, HNRNPA1L2, TPM1, 
NEGR1, MCFD2, HNRNPA1, SLC35E2B, ARHGAP32, RAB15, ADORA3, 
PPIP5K2, SYNRG, KCNN4, ANLN, Reck, MACC1, PBX3, MTOR, TWIST1, 
IKBKB, ESRRA, AP2B1, AURKAIP1, BCL2L12, C16orf58, CLU, CLUH, 
DENND6A, DIAPH1, FBXL18, GATAD2A, HSPA8, IER2, KMT2D, MAP2K3, 
PLEKHB2, POLR2E, PPP6R3, RNPS1, RPRD1B, SEC61A1, SNCG, WDR13, 
C21orf62, CARM1, CD274, JPT2, MINK1, RFK, TXNIP, VOPP1, ZNF284 
miR-199a-5p EZH2, IKBKB, CCNL1, LIF, JUNB, MED6, MECP2, ETS2, DDR1, EDN1, 
MAP3K11, HIF1A, SOX9, SMARCA2, CD44, TMEM54, SMAD4, SULT1E1, 
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GPR78, ERBB2, UNG, CAV1, SIRT1, HSPA5, ATF6, ERN1, KL, APOE, 
DNAJA4, ERBB3, CDH1, PTGS2, RNF11, ZNF544, TFDP2, ZNF844, PANK3, 
COL19A1, LIN7A, ARHGAP12, CTSC, RND1, NECTIN1, DRAM1, BECN1, 
MAFB, WNK1, NFKB1, ACVR1B, VEGFA, CDH2, SNAI1, GSK3B, FZD4, 
WNT2, JAG1, PSG11, PSG3, PIN1, C1orf226, PLEKHG2, PDE11A, SNTB1, 
SLC38A2, SESN2, RER1, PLXND1, MAP3K9, E2F3, COX15, TSC22D1, 
CEP120, SLC16A10, POLR2F, RCC1, DYNAP, PAX8, EXTL3, ZNF669, 
ZNF440, ZNF117, ZNF791, ZNF772, ZNF394, TUBG1, NAA15, DDX19B, 
RIC8A, C3orf36, SNRNP48, PSAPL1, AKAP17A, PLGRKT, TNFRSF13C, 
SLC8A1, CSGALNACT1, SERPINH1, TMOD2, DDX3X, ZNF525, ZNF195, 
ZNF415, ZNF468, ZNF611, ZNF215, ZNF286B, ZFP1, ZNF846, ZNF625, 
ZNF584, TRIM10, VAV3, OXSR1, PLPP4, A2ML1, RNF115, AGTRAP, 
NDUFS2, CHRFAM7A, CRIPT, POLA2, GATA6, CDK9, VPS53, PTCD2, 
SLC26A2, PODXL, ABCC1, TBC1D21, CENPO, CHCHD4, LAX1, SNAP25, 
HK2, KRAS, SMAD3, ETS1, CCR7, PDE4D, CTGF, TGFB2, PIK3CD, SETD2, 
LDLR, CLTC, RAB21, OSCP1, PIAS3, PSMD9, CDKN1C, ITGA3, FZD6, 
MAP4K3, TGFBR1, SLC27A1, C16orf58, CSNK2A1, DDI2, GM2A, NAB2, 
VASP, ZBTB37, QSOX1, ZDHHC9, DDHD1, XRRA1 
 
Supplemetary information, Table S5. Experimentally validated target genes of miRNA 
miR-155-5p, miR-497-5p and miR-199a-5p. 
 
hsa-miR-155-5p   
Term Gene number 
(%) 
adj p-value 
Pathways in cancer 
PI3K-Akt signaling pathway 
HTLV-I infection 
Hepatitis B 
FoxO signaling pathway 
Proteoglycans in cancer 
Focal adhesion 
Signaling pathways regulating pluripotency of stem cells 
TNF signaling pathway 
RNA transport 
Influenza A 
Hepatitis C 
Transcriptional misregulation in cancer 
Colorectal cancer 
T cell receptor signaling pathway 
Measles 
Chagas disease (American trypanosomiasis) 
Osteoclast differentiation 
AMPK signaling pathway 
Ubiquitin mediated proteolysis 
5,8 
4,1 
4 
3,2 
2,7 
2,7 
2,7 
2,5 
2,4 
2,4 
2,4 
2,3 
2,3 
2,2 
2,2 
2,2 
2,1 
2,1 
2 
2 
1,10E-05 
1,10E-02 
1,90E-04 
4,30E-06 
1,80E-04 
2,00E-02 
2,50E-02 
7,80E-04 
6,00E-05 
1,70E-02 
1,80E-02 
2,60E-03 
2,30E-02 
5,20E-07 
3,20E-04 
6,50E-03 
1,00E-03 
1,10E-02 
1,20E-02 
2,80E-02 
hsa-miR-497-5p   
Term Gene number 
(%) 
adj p-value 
Pathways in cancer 
PI3K-Akt signaling pathway 
MicroRNAs in cancer 
MAPK signaling pathway 
Viral carcinogenesis 
Focal adhesion 
Cell cycle 
Insulin signaling pathway 
Signaling pathways regulating pluripotency of stem cells 
Hepatitis B 
Proteoglycans in cancer 
HTLV-I infection 
7,2 
6,5 
4,8 
4,1 
3,9 
3,9 
3,7 
3,5 
3,5 
3,5 
3,5 
3,5 
1,60E-05 
1,80E-05 
1,20E-03 
4,10E-03 
1,30E-03 
1,30E-03 
2,50E-05 
2,50E-04 
2,70E-04 
3,40E-04 
5,90E-03 
3,90E-02 
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Epstein-Barr virus infection 
Ras signaling pathway 
Hippo signaling pathway 
Small cell lung cancer 
Prostate cancer 
FoxO signaling pathway 
Acute myeloid leukemia 
Chronic myeloid leukemia 
3,3 
3,3 
3 
2,8 
2,8 
2,8 
2,6 
2,6 
9,30E-03 
3,50E-02 
4,00E-03 
2,20E-04 
2,30E-04 
4,50E-03 
3,10E-05 
2,10E-04 
hsa-miR-199a-5p   
Term Gene number 
(%) 
adj p-value 
Pathways in cancer 
HTLV-I infection 
MicroRNAs in cancer 
Proteoglycans in cancer 
Pancreatic cancer 
Signaling pathways regulating pluripotency of stem cells 
Hippo signaling pathway 
Hepatitis B 
Adherens junction 
Chronic myeloid leukemia 
FoxO signaling pathway 
Colorectal cancer 
Prostate cancer 
HIF-1 signaling pathway 
TNF signaling pathway 
Cell cycle 
Non-alcoholic fatty liver disease (NAFLD) 
B cell receptor signaling pathway 
Small cell lung cancer 
Melanogenesis 
12 
9,6 
7,8 
7,2 
6,6 
6 
6 
5,4 
4,8 
4,8 
4,8 
4,2 
4,2 
4,2 
4,2 
4,2 
4,2 
3,6 
3,6 
3,6 
7,40E-06 
1,20E-05 
1,90E-03 
5,50E-04 
5,20E-07 
8,60E-04 
1,40E-03 
4,40E-03 
7,60E-04 
6,60E-04 
1,30E-02 
1,50E-03 
8,00E-03 
1,20E-02 
1,50E-02 
2,80E-02 
5,60E-02 
1,40E-02 
3,00E-02 
5,10E-02 
 
Supplementary information, Table S6. Pathway enrichment analysis on miR-155-5p, 
miR-497-5p and miR-199a-5p experimentally validated targets (top 20 KEGG pathways 
are shown). 
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EVs MSCs 
Order of inclusion 
by Ranking-PCA 
Variable loadings on PC1 Order of inclusion 
by Ranking-PCA 
Variable loadings on PC1 
1 hsa-miR-193b-3p 0.078085 1 hsa-miR-146b-3p 0.074598 
2 hsa-miR-142-5p 0.065747 2 hsa-miR-143-5p -0.07444 
3 hsa-miR-21-5p -0.07851 3 hsa-miR-28-5p 0.074518 
4 hsa-miR-222-3p -0.07351 4 hsa-miR-26b-3p -0.07445 
5 CALM -0.07058 5 hsa-miR-328-3p -0.07424 
6 TPM2 -0.07971 6 hsa-miR-148a-5p -0.07403 
7 hsa-miR-224-5p -0.06595 7 hsa-miR-146b-5p 0.073847 
8 hsa-miR-143-3p -0.0804 8 hsa-miR-125b-2-3p -0.07396 
9 hsa-miR-185-5p -0.05751 9 hsa-let-7f-5p 0.074328 
10 VIME -0.08363 10 hsa-miR-424-3p 0.073985 
11 hsa-miR-629-5p 0.055107 11 hsa-miR-874-3p -0.07424 
12 hsa-miR-126-3p 0.082491 12 hsa-miR-382-5p 0.074017 
13 hsa-miR-221-5p -0.06161 13 hsa-let-7i-5p 0.074116 
14 hsa-miR-132-3p 0.066751 14 hsa-miR-1276 -0.07221 
15 hsa-miR-485-5p -0.05812 15 hsa-miR-32-5p 0.073731 
16 MOES -0.07947 16 hsa-miR-149-5p -0.07415 
17 hsa-miR-199a-5p -0.05395 17 hsa-miR-28-3p 0.073542 
18 hsa-let-7a-5p -0.07549 18 hsa-let-7a-5p 0.073508 
19 MED6 0.080234 19 hsa-miR-155-5p 0.073754 
20 hsa-miR-23b-3p 0.048775 20 hsa-miR-92a-3p 0.07238 
21 hsa-miR-196a-5p -0.08271 21 hsa-miR-99a-5p 0.073624 
22 hsa-miR-146b-5p 0.052877 22 hsa-let-7b-3p -0.07447 
23 hsa-let-7i-5p -0.07156 23 hsa-miR-574-3p 0.074337 
24 APOB 0.063557 24 hsa-miR-3909 -0.07419 
25 hsa-miR-125b-5p -0.06961 25 hsa-miR-1296-5p -0.0737 
26 A2MG 0.060184 26 hsa-miR-7-5p 0.074119 
27 hsa-miR-31-3p 0.066542 27 hsa-miR-196a-5p 0.07339 
28 hsa-miR-16-2-3p -0.05081 28 hsa-miR-1287-5p -0.07365 
29 CO4A 0.079064 29 hsa-miR-30e-3p -0.07272 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Information, Table S7. Loadings on PC1 of the first 200 variables 
included by Ranking-PCA merging miRNA and proteomic data for both EVs and MSCs. 
Variables are listed in order of inclusion by Ranking-PCA. 
 
Protein 
Primary 
Antibody 
Primary 
Antibody 
dilution used 
Secondary 
Antibody 
Secondary 
Antibody 
dilution used 
CD44 
molecule 
CD44 
GeneTex 
(GTX628472) 
1:500 
Anti-Mouse 
Santa Cruz 
Biotechnology 
(sc-516102) 
1:2000 
CD63 
molecule 
CD63 
GeneTex 
(GTX17441) 
1:500 
Anti-Rabbit 
Santa Cruz 
Biotechnology 
(sc-2004) 
1:5000 
Endoglin 
CD105 
GeneTex 
(GTX100508) 
1:500 
Anti-Rabbit 
Santa Cruz 
Biotechnology 
(sc-2004) 
1:5000 
Galectin-3 
binding 
protein 
Mac-2BP 
Santa Cruz 
Biotechnology 
(sc-374541) 
1:100 
Anti-Mouse 
Santa Cruz 
Biotechnology 
(sc-516102) 
1:1000 
Melanoma cell 
adhesion 
molecule 
CD146 
GeneTex 
(GTX108777) 
1:500 
Anti-Rabbit 
Santa Cruz 
Biotechnology 
(sc-2004) 
1:5000 
Moesin 
Moesin 
Cell Signaling 
(#3150) 
1:1000 
Anti-Rabbit 
Santa Cruz 
Biotechnology 
(sc-2004) 
1:5000 
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Pentatraxin3 
Ptx3 
Santa Cruz 
Biotechnology 
(sc-373951) 
1:200 
Anti-Mouse 
Santa Cruz 
Biotechnology 
(sc-516102) 
1:1000 
S-100A6 
Calcyclin 
Santa Cruz 
Biotechnology 
(sc-271396) 
1:200 
Anti-Mouse 
Santa Cruz 
Biotechnology 
(sc-516102) 
1:1000 
 
Supplementary information, Table S8. List of antibodies used for western blotting 
validation 
 
 
 
 
 
 
 
